nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Ablative fractional laser-assisted treatments for keratinocyte carcinomas and its precursors–Clinical review and future perspectives
|
Erlendsson, Andrés M. |
|
|
163-164 |
C |
p. 185-194 |
artikel |
2 |
A brief history of long circulating nanoparticles
|
Haroon, H.B. |
|
|
163-164 |
C |
p. |
artikel |
3 |
Absorption, distribution, metabolism and excretion of the biomaterials used in Nanocarrier drug delivery systems
|
Su, Chong |
|
|
163-164 |
C |
p. 97-114 |
artikel |
4 |
A call for the standardised reporting of factors affecting the exogenous loading of extracellular vesicles with therapeutic cargos
|
Rankin-Turner, Stephanie |
|
|
163-164 |
C |
p. 479-491 |
artikel |
5 |
Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy
|
Woodsong, Cynthia |
|
2015 |
163-164 |
C |
p. 146-154 9 p. |
artikel |
6 |
Acellular and cellular approaches to improve diabetic wound healing
|
Cho, Hongkwan |
|
2019 |
163-164 |
C |
p. 267-288 |
artikel |
7 |
Acellular matrix in urethral reconstruction
|
Ribeiro-Filho, Leopoldo Alves |
|
2015 |
163-164 |
C |
p. 38-46 9 p. |
artikel |
8 |
A comprehensive comparison of DNA and RNA vaccines
|
Wang, Chunxi |
|
|
163-164 |
C |
p. |
artikel |
9 |
Acoustic behavior of microbubbles and implications for drug delivery
|
Kooiman, Klazina |
|
2014 |
163-164 |
C |
p. 28-48 21 p. |
artikel |
10 |
AcousticRobots: Smart acoustically powered micro-/nanoswimmers for precise biomedical applications
|
Wu, Gege |
|
|
163-164 |
C |
p. |
artikel |
11 |
Acoustic tweezers for targeted drug delivery
|
Guerassimoff, Léa |
|
|
163-164 |
C |
p. |
artikel |
12 |
Activatable dual-functional molecular agents for imaging-guided cancer therapy
|
Zhang, Peng |
|
|
163-164 |
C |
p. |
artikel |
13 |
Activatable fluorescence: From small molecule to nanoparticle
|
Luby, Benjamin M. |
|
2017 |
163-164 |
C |
p. 97-121 25 p. |
artikel |
14 |
Activatable fluorescent probes for real-time imaging-guided tumor therapy
|
Duan, Qi-Jia |
|
|
163-164 |
C |
p. |
artikel |
15 |
Adaptive immune responses to SARS-CoV-2
|
Forthal, Donald |
|
|
163-164 |
C |
p. 1-8 |
artikel |
16 |
Additive manufacturing in drug delivery: Innovative drug product design and opportunities for industrial application
|
Ragelle, Héloïse |
|
|
163-164 |
C |
p. |
artikel |
17 |
Additive manufacturing in respiratory sciences – Current applications and future prospects
|
Bock, Simon |
|
|
163-164 |
C |
p. |
artikel |
18 |
ADDR Editor’s Collection 2015
|
Ghandehari, Hamidreza |
|
2015 |
163-164 |
C |
p. 1-2 2 p. |
artikel |
19 |
ADDR Editor’s Collection 2017
|
Ghandehari, Hamidreza |
|
2017 |
163-164 |
C |
p. 1 |
artikel |
20 |
ADDR Editor’s Collection 2018
|
Ghandehari, Hamidreza |
|
2018 |
163-164 |
C |
p. 1 |
artikel |
21 |
ADDR Editor's Collection 2019
|
Ghandehari, Hamidreza |
|
|
163-164 |
C |
p. 1 |
artikel |
22 |
Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics
|
Hong, Enping |
|
2019 |
163-164 |
C |
p. 3-22 |
artikel |
23 |
Addressing the in vivo delivery of nucleic-acid nanostructure therapeutics
|
Alexander, Shana |
|
|
163-164 |
C |
p. |
artikel |
24 |
Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications
|
Ye, Dezhuang |
|
|
163-164 |
C |
p. |
artikel |
25 |
Adenosine and lipids: A forced marriage or a love match?
|
Rouquette, Marie |
|
|
163-164 |
C |
p. 233-244 |
artikel |
26 |
Adherence to minimal experimental requirements for defining extracellular vesicles and their functions
|
Poupardin, Rodolphe |
|
|
163-164 |
C |
p. |
artikel |
27 |
Advanced delivery systems for peptide antibiotics
|
Cesaro, Angela |
|
|
163-164 |
C |
p. |
artikel |
28 |
Advanced 3D imaging and organoid bioprinting for biomedical research and therapeutic applications
|
Maharjan, Sushila |
|
|
163-164 |
C |
p. |
artikel |
29 |
Advanced drug delivery 2020 and beyond: Perspectives on the future
|
Bae, You Han |
|
|
163-164 |
C |
p. 4-16 |
artikel |
30 |
Advanced drug delivery 2020 - Parts 1, 2 and 3
|
Ghandehari, H. |
|
|
163-164 |
C |
p. 1-2 |
artikel |
31 |
Advanced drug delivery systems and artificial skin grafts for skin wound healing
|
Kim, Hye Sung |
|
2019 |
163-164 |
C |
p. 209-239 |
artikel |
32 |
Advanced engineered nanoparticulate platforms to address key biological barriers for delivering chemotherapeutic agents to target sites
|
Cao, Jun |
|
|
163-164 |
C |
p. 170-188 |
artikel |
33 |
Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics
|
Artzy-Schnirman, Arbel |
|
|
163-164 |
C |
p. |
artikel |
34 |
Advanced imaging techniques for tracking drug dynamics at the subcellular level
|
Zhang, Chengying |
|
|
163-164 |
C |
p. |
artikel |
35 |
Advanced in vitro models of vascular biology: Human induced pluripotent stem cells and organ-on-chip technology
|
Cochrane, Amy |
|
2019 |
163-164 |
C |
p. 68-77 |
artikel |
36 |
Advanced light delivery materials and systems for photomedicines
|
Kim, Seong-Jong |
|
|
163-164 |
C |
p. |
artikel |
37 |
Advanced methodologies for cocrystal synthesis
|
Douroumis, Dennis |
|
2017 |
163-164 |
C |
p. 178-195 18 p. |
artikel |
38 |
Advanced microbiome therapeutics for oral delivery of peptides and proteins: Advances, challenges, and opportunities
|
Gelli, Hitesh P. |
|
|
163-164 |
C |
p. |
artikel |
39 |
Advanced nanomedicines for the treatment of inflammatory diseases
|
Brusini, Romain |
|
|
163-164 |
C |
p. 161-178 |
artikel |
40 |
Advanced nanotherapies to promote neuroregeneration in the injured newborn brain
|
Arteaga Cabeza, Olatz |
|
|
163-164 |
C |
p. 19-37 |
artikel |
41 |
Advanced optical imaging for the rational design of nanomedicines
|
Ortiz-Perez, Ana |
|
|
163-164 |
C |
p. |
artikel |
42 |
Advancedoral vaccine delivery strategies for improving the immunity
|
Zhang, Yuandong |
|
|
163-164 |
C |
p. |
artikel |
43 |
Advanced structural characterisation of pharmaceuticals using nano-thermal analysis (nano-TA)
|
Goh, Choon Fu |
|
|
163-164 |
C |
p. |
artikel |
44 |
Advanced theragnostics for the central nervous system (CNS) and neurological disorders using functional inorganic nanomaterials
|
Conklin, Brandon |
|
|
163-164 |
C |
p. |
artikel |
45 |
Advanced vaccine delivery
|
Ma, Guanghui |
|
|
163-164 |
C |
p. |
artikel |
46 |
Advancement in integrin facilitated drug delivery
|
Arosio, Daniela |
|
2016 |
163-164 |
C |
p. 111-143 33 p. |
artikel |
47 |
Advancements in brachytherapy
|
Tanderup, Kari |
|
2017 |
163-164 |
C |
p. 15-25 11 p. |
artikel |
48 |
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics
|
Kang, Diana D. |
|
|
163-164 |
C |
p. |
artikel |
49 |
Advances and controversies in studying sunscreen delivery and toxicity
|
Yamada, Miko |
|
|
163-164 |
C |
p. 72-86 |
artikel |
50 |
Advances and future perspectives in epithelial drug delivery
|
Mohammed, Yousuf |
|
|
163-164 |
C |
p. |
artikel |
51 |
Advances and hurdles to clinical translation of RNAi therapeutics
|
Kwon, Ick Chan |
|
2016 |
163-164 |
C |
p. 1- 1 p. |
artikel |
52 |
Advances and new technologies in the treatment of burn injury
|
Wang, Yiwei |
|
2018 |
163-164 |
C |
p. 1-2 |
artikel |
53 |
Advances, challenges, and future directions in the clinical translation of ECM biomaterials for regenerative medicine applications
|
Capella-Monsonís, Héctor |
|
|
163-164 |
C |
p. |
artikel |
54 |
Advances in bacteria-based therapy for drug delivery
|
Liu, Jinyao |
|
|
163-164 |
C |
p. |
artikel |
55 |
Advances in biocompatibility and physico-chemical characterization of microspheres for cell encapsulation
|
Rokstad, Anne Mari A. |
|
2014 |
163-164 |
C |
p. 111-130 20 p. |
artikel |
56 |
Advances in biosensing strategies for HIV-1 detection, diagnosis, and therapeutic monitoring
|
Lifson, Mark A. |
|
|
163-164 |
C |
p. 90-104 |
artikel |
57 |
Advances in cancer stem cell targeting: How to strike the evil at its root
|
Pützer, Brigitte M. |
|
2017 |
163-164 |
C |
p. 89-107 |
artikel |
58 |
Advances in carbon nanomaterials and their polymeric composites in neural tissue engineering
|
Kanjilal, Baishali |
|
|
163-164 |
C |
p. |
artikel |
59 |
Advances in computationally modeling human oral bioavailability
|
Wang, Junmei |
|
2015 |
163-164 |
C |
p. 11-16 6 p. |
artikel |
60 |
Advances in development of exosomes for ophthalmic therapeutics
|
Tian, Ying |
|
|
163-164 |
C |
p. |
artikel |
61 |
Advances in drug delivery for women’s health: A matter of gender equity
|
das Neves, José |
|
|
163-164 |
C |
p. |
artikel |
62 |
Advances in enhancing photoprotection of sunscreens using hydrocarbon film formers and carbon nanomaterials
|
Addae, Ajoa J. |
|
|
163-164 |
C |
p. |
artikel |
63 |
Advances in gene-based vaccine platforms to address the COVID-19 pandemic
|
Pushparajah, Deborah |
|
|
163-164 |
C |
p. 113-141 |
artikel |
64 |
Advances in genome editing for genetic hearing loss
|
Ding, Ning |
|
|
163-164 |
C |
p. 118-133 |
artikel |
65 |
Advances in image-guided drug delivery for antibacterial therapy
|
Huang, Haiyan |
|
|
163-164 |
C |
p. |
artikel |
66 |
Advances in imaging probes and optical microendoscopic imaging techniques for early in vivo cancer assessment
|
Khemthongcharoen, Numfon |
|
2014 |
163-164 |
C |
p. 53-74 22 p. |
artikel |
67 |
Advances in immunotherapy of type I diabetes
|
Ni, Qianqian |
|
2019 |
163-164 |
C |
p. 83-91 |
artikel |
68 |
Advances in keratinocyte delivery in burn wound care
|
ter Horst, Britt |
|
2018 |
163-164 |
C |
p. 18-32 |
artikel |
69 |
Advances in local drug delivery technologies for improved rheumatoid arthritis therapy
|
An, Xiaoran |
|
|
163-164 |
C |
p. |
artikel |
70 |
Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention
|
Krovi, Sai Archana |
|
|
163-164 |
C |
p. |
artikel |
71 |
Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection
|
Ullah Nayan, Mohammad |
|
|
163-164 |
C |
p. |
artikel |
72 |
Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems
|
Maeki, Masatoshi |
|
2018 |
163-164 |
C |
p. 84-100 |
artikel |
73 |
Advances in modular control of CAR-T therapy with adapter-mediated CARs
|
McCue, Amelia C. |
|
|
163-164 |
C |
p. |
artikel |
74 |
Advances in mRNA non-viral delivery approaches
|
Ibba, Maria L. |
|
|
163-164 |
C |
p. |
artikel |
75 |
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
|
Han, Geonhee |
|
|
163-164 |
C |
p. |
artikel |
76 |
Advances in nano-based inner ear delivery systems for the treatment of sensorineural hearing loss
|
Li, Lilun |
|
2017 |
163-164 |
C |
p. 2-12 11 p. |
artikel |
77 |
Advances in nanoparticle mediated targeting of RNA binding protein for cancer
|
Kashikar, Rama |
|
|
163-164 |
C |
p. |
artikel |
78 |
Advances in peptide-mediated cytosolic delivery of proteins
|
Sánchez-Navarro, Macarena |
|
|
163-164 |
C |
p. 187-198 |
artikel |
79 |
Advances in photoactivated carbon-based nanostructured materials for targeted cancer therapy
|
Eftekharifar, Maryam |
|
|
163-164 |
C |
p. |
artikel |
80 |
Advances in powder bed fusion 3D printing in drug delivery and healthcare
|
Awad, Atheer |
|
|
163-164 |
C |
p. 406-424 |
artikel |
81 |
Advances in Salmonella Typhimurium-based drug delivery system for cancer therapy
|
Chen, Wenfei |
|
|
163-164 |
C |
p. |
artikel |
82 |
Advances in Single-component inorganic nanostructures for photoacoustic imaging guided photothermal therapy
|
Zhu, Houjuan |
|
|
163-164 |
C |
p. |
artikel |
83 |
Advances in solid formulation of pharmaceutical biologics
|
(Tony) Zhou, Qi |
|
|
163-164 |
C |
p. |
artikel |
84 |
Advances in the design and delivery of RNA vaccines for infectious diseases
|
Lokras, Abhijeet Girish |
|
|
163-164 |
C |
p. |
artikel |
85 |
Advances in the development of antimicrobial peptides and proteins for inhaled therapy
|
Wang, Yuncheng |
|
|
163-164 |
C |
p. |
artikel |
86 |
Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems
|
Hadji, Hicheme |
|
|
163-164 |
C |
p. |
artikel |
87 |
Advances in transdermal insulin delivery
|
Zhang, Yuqi |
|
2019 |
163-164 |
C |
p. 51-70 |
artikel |
88 |
Advances of bacteria-based delivery systems for modulating tumor microenvironment
|
Li, Shuping |
|
|
163-164 |
C |
p. |
artikel |
89 |
Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages
|
Yu, Wenqi |
|
|
163-164 |
C |
p. |
artikel |
90 |
Advances on colorectal cancer 3D models: The needed translational technology for nanomedicine screening
|
Castro, Flávia |
|
|
163-164 |
C |
p. |
artikel |
91 |
Advances on erythrocyte-mimicking nanovehicles to overcome barriers in biological microenvironments
|
Castro, Flávia |
|
|
163-164 |
C |
p. 312-339 |
artikel |
92 |
Advances on non-invasive physically triggered nucleic acid delivery from nanocarriers
|
Do, Hai Doan |
|
2019 |
163-164 |
C |
p. 3-17 |
artikel |
93 |
Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade
|
Choi, Youngjin |
|
|
163-164 |
C |
p. |
artikel |
94 |
Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin
|
Shah, Shrey A. |
|
|
163-164 |
C |
p. |
artikel |
95 |
Advancing pharmacy and healthcare with virtual digital technologies
|
Trenfield, Sarah J. |
|
|
163-164 |
C |
p. |
artikel |
96 |
Advancing the cellular and molecular therapy for intervertebral disc disease
|
Sakai, Daisuke |
|
2015 |
163-164 |
C |
p. 159-171 13 p. |
artikel |
97 |
Advancing tumor microenvironment and lymphoid tissue research through 3D bioprinting and biofabrication
|
Mazzaglia, Corrado |
|
|
163-164 |
C |
p. |
artikel |
98 |
Aerosol pulmonary immune engineering
|
Sudduth, Emma R. |
|
|
163-164 |
C |
p. |
artikel |
99 |
Aggregation-induced emission (AIE) fluorophores as imaging tools to trace the biological fate of nano-based drug delivery systems
|
Wang, Yufei |
|
|
163-164 |
C |
p. 161-176 |
artikel |
100 |
Aggregation-induced emission (AIE)-guided dynamic assembly for disease imaging and therapy
|
Wang, He-Ping |
|
|
163-164 |
C |
p. |
artikel |
101 |
Agony of choice: How anesthetics affect the composition and function of extracellular vesicles
|
Abel, Frederik |
|
|
163-164 |
C |
p. |
artikel |
102 |
A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics
|
Ranjbar, Sheyda |
|
|
163-164 |
C |
p. |
artikel |
103 |
Air-Liquid interface cultures to model drug delivery through the mucociliary epithelial barrier
|
Lee, Rhianna E |
|
|
163-164 |
C |
p. |
artikel |
104 |
Alginate biomaterial for the treatment of myocardial infarction: Progress, translational strategies, and clinical outlook
|
Ruvinov, Emil |
|
2016 |
163-164 |
C |
p. 54-76 23 p. |
artikel |
105 |
Allergen to asset: Pollen-based drug delivery systems
|
Ibrahim, Mohammed Shahrudin |
|
|
163-164 |
C |
p. |
artikel |
106 |
Altered peripheral factors affecting the absorption, distribution, metabolism, and excretion of oral medicines in Alzheimer’s disease
|
Waller, Elka S. |
|
|
163-164 |
C |
p. |
artikel |
107 |
A minimalist's approach for DNA nanoconstructions
|
Zuo, Hua |
|
|
163-164 |
C |
p. 22-28 |
artikel |
108 |
α-Amino acid N-carboxyanhydride (NCA)-derived synthetic polypeptides for nucleic acids delivery
|
Liu, Yong |
|
|
163-164 |
C |
p. 139-163 |
artikel |
109 |
A moderate thermal dose is sufficient for effective free and TSL based thermochemotherapy
|
van Rhoon, G.C. |
|
|
163-164 |
C |
p. 145-156 |
artikel |
110 |
Amorphous Pharmaceutical Solids
|
Descamps, Marc |
|
2016 |
163-164 |
C |
p. 1-2 2 p. |
artikel |
111 |
Amorphous powders for inhalation drug delivery
|
Chen, Lan |
|
2016 |
163-164 |
C |
p. 102-115 14 p. |
artikel |
112 |
Amorphous solid dispersions: Rational selection of a manufacturing process
|
Vasconcelos, Teófilo |
|
2016 |
163-164 |
C |
p. 85-101 17 p. |
artikel |
113 |
An emerging focus on lipids in extracellular vesicles
|
Skotland, Tore |
|
|
163-164 |
C |
p. 308-321 |
artikel |
114 |
An EPR-Independent extravasation Strategy: Deformable leukocytes as vehicles for improved solid tumor therapy
|
Wu, Huayu |
|
|
163-164 |
C |
p. |
artikel |
115 |
A new chapter in pharmaceutical manufacturing: 3D-printed drug products
|
Norman, James |
|
2017 |
163-164 |
C |
p. 39-50 12 p. |
artikel |
116 |
A new era in brain drug delivery: Integrating multivalency and computational optimisation for blood–brain barrier permeation
|
Porro, Giulia |
|
|
163-164 |
C |
p. |
artikel |
117 |
A new era in posterior segment ocular drug delivery: Translation of systemic, cell-targeted, dendrimer-based therapies
|
Kannan, Rangaramanujam M. |
|
|
163-164 |
C |
p. |
artikel |
118 |
A new era of targeting cystic fibrosis with non-viral delivery of genomic medicines
|
Turuvekere Vittala Murthy, Namratha |
|
|
163-164 |
C |
p. |
artikel |
119 |
Angiogenesis regulation by nanocarriers bearing RNA interference
|
Ofek, Paula |
|
2017 |
163-164 |
C |
p. 3-19 |
artikel |
120 |
Animal models for analysis of immunological responses to nanomaterials: Challenges and considerations
|
Zamboni, William C. |
|
2018 |
163-164 |
C |
p. 82-96 |
artikel |
121 |
Animal models of smoke inhalation injury and related acute and chronic lung diseases
|
Reczyńska, Katarzyna |
|
2018 |
163-164 |
C |
p. 107-134 |
artikel |
122 |
An integrated perspective for the diagnosis and therapy of neurodevelopmental disorders – From an engineering point of view
|
Mintz Hemed, Nofar |
|
|
163-164 |
C |
p. |
artikel |
123 |
An old problem with new solutions: Strategies to improve vaccine efficacy in the elderly
|
Bell, Matthew R. |
|
|
163-164 |
C |
p. |
artikel |
124 |
A novel platform for cancer therapy using extracellular vesicles
|
Tominaga, Naoomi |
|
2015 |
163-164 |
C |
p. 50-55 6 p. |
artikel |
125 |
An overview of in vitro 3D models of the blood-brain barrier as a tool to predict the in vivo permeability of nanomedicines
|
Pérez-López, Alexandre |
|
|
163-164 |
C |
p. |
artikel |
126 |
An overview of in vitro, ex vivo and in vivo models for studying the transport of drugs across intestinal barriers
|
Xu, Yining |
|
|
163-164 |
C |
p. |
artikel |
127 |
An overview of microRNAs
|
Hammond, Scott M. |
|
2015 |
163-164 |
C |
p. 3-14 12 p. |
artikel |
128 |
An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers
|
Ando, Hidenori |
|
|
163-164 |
C |
p. 27-36 |
artikel |
129 |
Anti-aging properties of phytoconstituents and phyto-nanoemulsions and their application in managing aging-related diseases
|
Xue, Feng |
|
|
163-164 |
C |
p. |
artikel |
130 |
Antibiotic-containing polymers for localized, sustained drug delivery
|
Stebbins, Nicholas D. |
|
2014 |
163-164 |
C |
p. 77-87 11 p. |
artikel |
131 |
Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy
|
Hutmacher, Cornelia |
|
2019 |
163-164 |
C |
p. 67-91 |
artikel |
132 |
Antibody Directed Enzyme Prodrug Therapy (ADEPT): Trials and tribulations
|
Sharma, Surinder K. |
|
2017 |
163-164 |
C |
p. 2-7 |
artikel |
133 |
Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers
|
Armstrong, Georgina B |
|
|
163-164 |
C |
p. |
artikel |
134 |
Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment
|
Zhang, Jing |
|
|
163-164 |
C |
p. 245-273 |
artikel |
135 |
Antifibrotic strategies for medical devices
|
Welch, Nicholas G. |
|
|
163-164 |
C |
p. 109-120 |
artikel |
136 |
Antifungal therapy: Novel drug delivery strategies driven by new targets
|
Wu, Shuang |
|
|
163-164 |
C |
p. |
artikel |
137 |
Antimicrobial blue light: A ‘Magic Bullet’ for the 21st century and beyond?
|
Leanse, Leon G. |
|
|
163-164 |
C |
p. |
artikel |
138 |
Antimicrobial hydrogels: A new weapon in the arsenal against multidrug-resistant infections
|
Ng, Victor W.L. |
|
2014 |
163-164 |
C |
p. 46-62 17 p. |
artikel |
139 |
Antimicrobial peptides towards clinical application: Delivery and formulation
|
Wang, Cheng |
|
|
163-164 |
C |
p. |
artikel |
140 |
Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients
|
Ciofu, Oana |
|
2015 |
163-164 |
C |
p. 7-23 17 p. |
artikel |
141 |
Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals
|
Kozma, Gergely Tibor |
|
|
163-164 |
C |
p. 163-175 |
artikel |
142 |
Antisense oligonucleotides in therapy for neurodegenerative disorders
|
Evers, Melvin M. |
|
2015 |
163-164 |
C |
p. 90-103 14 p. |
artikel |
143 |
Anti-thrombotic technologies for medical devices
|
Lavery, Karen S. |
|
2017 |
163-164 |
C |
p. 2-11 10 p. |
artikel |
144 |
Application of advances in endocytosis and membrane trafficking to drug delivery
|
Ju, Yaping |
|
|
163-164 |
C |
p. 118-141 |
artikel |
145 |
Application of aptamers for in vivo molecular imaging and theranostics
|
Bouvier-Müller, Alix |
|
2018 |
163-164 |
C |
p. 94-106 |
artikel |
146 |
Application of cell encapsulation for controlled delivery of biological therapeutics
|
Orive, G. |
|
2014 |
163-164 |
C |
p. 3-14 12 p. |
artikel |
147 |
Application of colloidal photonic crystals in study of organoids
|
Huang, Kai |
|
|
163-164 |
C |
p. |
artikel |
148 |
Application of Förster Resonance Energy Transfer (FRET) technique to elucidate intracellular and In Vivo biofate of nanomedicines
|
Chen, Tongkai |
|
|
163-164 |
C |
p. 177-205 |
artikel |
149 |
Application of MIDD to accelerate the development of anti-infectives: Current status and future perspectives
|
Mak, Wen Yao |
|
|
163-164 |
C |
p. |
artikel |
150 |
Application of super-resolution microscopy in mitochondria-dynamic diseases
|
Zou, Weiwei |
|
|
163-164 |
C |
p. |
artikel |
151 |
Application of UV dissolution imaging to pharmaceutical systems
|
Brown, Benedict |
|
|
163-164 |
C |
p. |
artikel |
152 |
Applications of AFM-IR for drug delivery vector characterization: infrared, thermal, and mechanical characterization at the nanoscale
|
Zhang, Jing |
|
|
163-164 |
C |
p. |
artikel |
153 |
Applications of DNA-based nanostructures in immunotherapy
|
Li, Dandan |
|
|
163-164 |
C |
p. |
artikel |
154 |
Applications of focused ultrasound-mediated blood-brain barrier opening
|
Gorick, Catherine M. |
|
|
163-164 |
C |
p. |
artikel |
155 |
Applications of pharmacometrics in drug development
|
Xiong, Yuan |
|
|
163-164 |
C |
p. |
artikel |
156 |
Applications of Raman spectroscopy in skin research — From skin physiology and diagnosis up to risk assessment and dermal drug delivery
|
Franzen, Lutz |
|
2015 |
163-164 |
C |
p. 91-104 14 p. |
artikel |
157 |
Applying nanomedicine in maladaptive inflammation and angiogenesis
|
Alaarg, Amr |
|
2017 |
163-164 |
C |
p. 143-158 |
artikel |
158 |
Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment
|
Pinel, Sophie |
|
2019 |
163-164 |
C |
p. 344-357 |
artikel |
159 |
Approaches to surface engineering of extracellular vesicles
|
Richter, Maximilian |
|
|
163-164 |
C |
p. 416-426 |
artikel |
160 |
A proposed mathematical description of in vivo nanoparticle delivery
|
Wu, Jamie L.Y. |
|
|
163-164 |
C |
p. |
artikel |
161 |
Aptamer-based applications in delivering cancer gene therapies and beyond: state of the art and the missing links to clinical translation
|
Coppola, Gabriele |
|
|
163-164 |
C |
p. |
artikel |
162 |
Aptamer-based targeted therapy
|
Zhu, Guizhi |
|
2018 |
163-164 |
C |
p. 65-78 |
artikel |
163 |
Aptamer chemistry
|
Röthlisberger, Pascal |
|
2018 |
163-164 |
C |
p. 3-21 |
artikel |
164 |
Aptamer-guided nanomedicines for anticancer drug delivery
|
Alshaer, Walhan |
|
2018 |
163-164 |
C |
p. 122-137 |
artikel |
165 |
Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers
|
Zhou, Gang |
|
2018 |
163-164 |
C |
p. 107-121 |
artikel |
166 |
Aptamers in Therapeutics and Drug Delivery
|
Fattal, Elias |
|
2018 |
163-164 |
C |
p. 1-2 |
artikel |
167 |
Aptamers: Uptake mechanisms and intracellular applications
|
Yoon, Sorah |
|
2018 |
163-164 |
C |
p. 22-35 |
artikel |
168 |
A quantitative view on multivalent nanomedicine targeting
|
Woythe, Laura |
|
|
163-164 |
C |
p. 1-21 |
artikel |
169 |
Are caveolae a cellular entry route for non-viral therapeutic delivery systems?
|
Rewatkar, Prarthana V. |
|
2015 |
163-164 |
C |
p. 92-108 17 p. |
artikel |
170 |
A review of drug delivery systems for capsule endoscopy
|
Munoz, Fredy |
|
2014 |
163-164 |
C |
p. 77-85 9 p. |
artikel |
171 |
A review of emerging technologies enabling improved solid oral dosage form manufacturing and processing
|
Sohail Arshad, Muhammad |
|
|
163-164 |
C |
p. |
artikel |
172 |
A review of upper airway physiology relevant to the delivery and deposition of inhalation aerosols
|
Mekonnen, Taye |
|
|
163-164 |
C |
p. |
artikel |
173 |
A review on core–shell structured unimolecular nanoparticles for biomedical applications
|
Chen, Guojun |
|
2018 |
163-164 |
C |
p. 58-72 |
artikel |
174 |
Articular fibrocartilage - Why does hyaline cartilage fail to repair?
|
Armiento, Angela R. |
|
2019 |
163-164 |
C |
p. 289-305 |
artikel |
175 |
Artificial intelligence and machine learning assisted drug delivery for effective treatment of infectious diseases
|
He, Sheng |
|
|
163-164 |
C |
p. |
artikel |
176 |
Artificial intelligence to bring nanomedicine to life
|
Serov, Nikita |
|
|
163-164 |
C |
p. |
artikel |
177 |
A slippery slope: On the origin, role and physiology of mucus
|
Taherali, Farhan |
|
2018 |
163-164 |
C |
p. 16-33 |
artikel |
178 |
A systematic overview of strategies for photosensitizer and light delivery in antibacterial photodynamic therapy for lung infections
|
Shleeva, Margarita O. |
|
|
163-164 |
C |
p. |
artikel |
179 |
A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy
|
Seya, Tsukasa |
|
|
163-164 |
C |
p. 37-43 |
artikel |
180 |
Automation and data-driven design of polymer therapeutics
|
Upadhya, Rahul |
|
|
163-164 |
C |
p. 1-28 |
artikel |
181 |
Autophagy in the cancer-immunity dialogue
|
Yamazaki, Takahiro |
|
|
163-164 |
C |
p. 40-50 |
artikel |
182 |
A window into the brain: Tools to assess pre-clinical efficacy of biomaterials-based therapies on central nervous system disorders
|
Samal, Juhi |
|
|
163-164 |
C |
p. 68-145 |
artikel |
183 |
Bacteria and bacterial derivatives as delivery carriers for immunotherapy
|
Kang, Sae-Ryung |
|
|
163-164 |
C |
p. |
artikel |
184 |
Bacteria-based bioactive materials for cancer imaging and therapy
|
Chen, Ying |
|
|
163-164 |
C |
p. |
artikel |
185 |
Bacterial extracellular vesicles: Understanding biology promotes applications as nanopharmaceuticals
|
Jahromi, Leila Pourtalebi |
|
|
163-164 |
C |
p. 125-140 |
artikel |
186 |
Bacterially mediated drug delivery and therapeutics: Strategies and advancements
|
Wu, Leyang |
|
|
163-164 |
C |
p. |
artikel |
187 |
Bacterial membrane vesicles for vaccine applications
|
Krishnan, Nishta |
|
|
163-164 |
C |
p. |
artikel |
188 |
Bacteriophage-based biomaterials for tissue regeneration
|
Cao, Binrui |
|
2019 |
163-164 |
C |
p. 73-95 |
artikel |
189 |
Bacteriophage interactions with mammalian tissue: Therapeutic applications
|
Huh, Haein |
|
2019 |
163-164 |
C |
p. 4-17 |
artikel |
190 |
Bacteriophage-mediated modulation of microbiota for diseases treatment
|
Zhang, Yu |
|
|
163-164 |
C |
p. |
artikel |
191 |
Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases
|
Tao, Pan |
|
2019 |
163-164 |
C |
p. 57-72 |
artikel |
192 |
Basic biology and therapeutic implications of lncRNA
|
Khorkova, O. |
|
2015 |
163-164 |
C |
p. 15-24 10 p. |
artikel |
193 |
Battle of GLP-1 delivery technologies
|
Yu, Minzhi |
|
2018 |
163-164 |
C |
p. 113-130 |
artikel |
194 |
BDDCS, the Rule of 5 and drugability
|
Benet, Leslie Z. |
|
2016 |
163-164 |
C |
p. 89-98 10 p. |
artikel |
195 |
Be a GEM: Biocontained, environmentally applied, genetically engineered microbes
|
Moon, Tae Seok |
|
|
163-164 |
C |
p. |
artikel |
196 |
Bench-to-bedside translation of dendrimers: Reality or utopia? A concise analysis
|
Mignani, Serge |
|
2018 |
163-164 |
C |
p. 73-81 |
artikel |
197 |
Beyond conventional antibiotics — New directions for combination products to combat biofilm
|
Bayramov, Danir Fanisovich |
|
2017 |
163-164 |
C |
p. 48-60 13 p. |
artikel |
198 |
Beyond PEGylation: Alternative surface-modification of nanoparticles with mucus-inert biomaterials
|
Khutoryanskiy, Vitaliy V. |
|
2018 |
163-164 |
C |
p. 140-149 |
artikel |
199 |
Beyond the adverse effects of the systemic route: Exploiting nanocarriers for the topical treatment of skin cancers
|
da Silva Gomes, Beatriz |
|
|
163-164 |
C |
p. |
artikel |
200 |
Beyond the borders — Biomedical applications of non-linear Raman microscopy
|
Winterhalder, Martin Josef |
|
2015 |
163-164 |
C |
p. 135-144 10 p. |
artikel |
201 |
Bioactive 2D nanomaterials for neural repair and regeneration
|
He, Xiaolie |
|
|
163-164 |
C |
p. |
artikel |
202 |
Bioactive lipids, inflammation and chronic diseases
|
Leuti, Alessandro |
|
|
163-164 |
C |
p. 133-169 |
artikel |
203 |
Bioactive scaffolds based on elastin-like materials for wound healing
|
Rodríguez-Cabello, J. Carlos |
|
|
163-164 |
C |
p. 118-133 |
artikel |
204 |
Biochemical studies on the structure–function relationship of major drug transporters in the ATP-binding cassette family and solute carrier family
|
Hong, Mei |
|
2017 |
163-164 |
C |
p. 3-20 18 p. |
artikel |
205 |
Biocompatibility and safety of PLA and its copolymers
|
Ramot, Yuval |
|
2016 |
163-164 |
C |
p. 153-162 |
artikel |
206 |
Bioconjugates for targeted delivery of therapeutic oligonucleotides
|
Ming, Xin |
|
2015 |
163-164 |
C |
p. 81-89 9 p. |
artikel |
207 |
Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges
|
Skotland, Tore |
|
|
163-164 |
C |
p. |
artikel |
208 |
Bioengineered baculoviruses as new class of therapeutics using micro and nanotechnologies: Principles, prospects and challenges
|
Paul, Arghya |
|
2014 |
163-164 |
C |
p. 115-130 16 p. |
artikel |
209 |
Bioengineered cellular and cell membrane-derived vehicles for actively targeted drug delivery: So near and yet so far
|
Thanuja M.Y., |
|
2018 |
163-164 |
C |
p. 57-80 |
artikel |
210 |
Bioengineered elastin- and silk-biomaterials for drug and gene delivery
|
Chambre, Laura |
|
|
163-164 |
C |
p. 186-198 |
artikel |
211 |
Bioengineered heparins and heparan sulfates
|
Fu, Li |
|
2016 |
163-164 |
C |
p. 237-249 13 p. |
artikel |
212 |
Bioengineering 3D environments for cancer models
|
Alemany-Ribes, Mireia |
|
2014 |
163-164 |
C |
p. 40-49 10 p. |
artikel |
213 |
Bioengineering methods for myocardial regeneration
|
Parsa, Hesam |
|
2016 |
163-164 |
C |
p. 195-202 8 p. |
artikel |
214 |
Bioengineering of virus-like particles as dynamic nanocarriers for in vivo delivery and targeting to solid tumours
|
Suffian, Izzat F.B.M |
|
|
163-164 |
C |
p. |
artikel |
215 |
Bioengineering strategies for inducing tolerance in autoimmune diabetes
|
Baekkeskov, Steinunn |
|
2017 |
163-164 |
C |
p. 256-265 |
artikel |
216 |
Bioengineering toolkits for potentiating organoid therapeutics
|
Park, Sewon |
|
|
163-164 |
C |
p. |
artikel |
217 |
Bioequivalence assessment of pharmaceutical aerosol products through IVIVC
|
Sandell, Dennis |
|
|
163-164 |
C |
p. |
artikel |
218 |
Bioinspired drug delivery strategies for repurposing conventional antibiotics against intracellular infections
|
Subramaniam, Santhni |
|
|
163-164 |
C |
p. |
artikel |
219 |
Biological and intracellular fates of drug nanocrystals through different delivery routes: Recent development enabled by bioimaging and PK modeling
|
Lv, Yongjiu |
|
|
163-164 |
C |
p. |
artikel |
220 |
Biologics and their delivery systems: Trends in myocardial infarction
|
Borrelli, Matthew A. |
|
|
163-164 |
C |
p. 181-215 |
artikel |
221 |
Biologics for tendon repair
|
Docheva, Denitsa |
|
2015 |
163-164 |
C |
p. 222-239 18 p. |
artikel |
222 |
Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer’s disease
|
Vandendriessche, Charysse |
|
|
163-164 |
C |
p. |
artikel |
223 |
Biomarkers of spinal cord injury and ensuing bladder dysfunction
|
Cruz, Célia Duarte |
|
2015 |
163-164 |
C |
p. 153-159 7 p. |
artikel |
224 |
Biomaterial-assisted macrophage cell therapy for regenerative medicine
|
Sung, Samuel |
|
|
163-164 |
C |
p. |
artikel |
225 |
Biomaterial-based delivery for skeletal muscle repair
|
Cezar, Christine A. |
|
2015 |
163-164 |
C |
p. 188-197 10 p. |
artikel |
226 |
Biomaterial-based delivery of nucleic acids for tissue regeneration
|
Zhuang, Yaping |
|
|
163-164 |
C |
p. |
artikel |
227 |
Biomaterials based on phages and other viruses
|
Yang, Mingying |
|
2019 |
163-164 |
C |
p. 1-3 |
artikel |
228 |
Biomaterials releasing drug responsively to promote wound healing via regulation of pathological microenvironment
|
Li, Haisheng |
|
|
163-164 |
C |
p. |
artikel |
229 |
Biomaterial strategies for engineering implants for enhanced osseointegration and bone repair
|
Agarwal, Rachit |
|
2015 |
163-164 |
C |
p. 53-62 10 p. |
artikel |
230 |
Biomaterial strategies for generating therapeutic immune responses
|
Kelly, Sean H. |
|
2017 |
163-164 |
C |
p. 3-18 |
artikel |
231 |
Biomatrices for bladder reconstruction
|
Lin, Hsueh-Kung |
|
2015 |
163-164 |
C |
p. 47-63 17 p. |
artikel |
232 |
Biomechanical conditioning of tissue engineered heart valves: Too much of a good thing?
|
Parvin Nejad, Shouka |
|
2016 |
163-164 |
C |
p. 161-175 15 p. |
artikel |
233 |
Biomechanical forces in the skeleton and their relevance to bone metastasis: Biology and engineering considerations
|
Lynch, Maureen E. |
|
2014 |
163-164 |
C |
p. 119-134 16 p. |
artikel |
234 |
Biomedical application of small extracellular vesicles in cancer treatment
|
Araujo-Abad, Salome |
|
|
163-164 |
C |
p. |
artikel |
235 |
Biomedical applications of polymers derived by reversible addition – fragmentation chain-transfer (RAFT)
|
Fairbanks, Benjamin D. |
|
2015 |
163-164 |
C |
p. 141-152 12 p. |
artikel |
236 |
Biomedical engineering of two-dimensional MXenes
|
Huang, Hui |
|
|
163-164 |
C |
p. |
artikel |
237 |
Biomembrane-based nanostructures for cancer targeting and therapy: From synthetic liposomes to natural biomembranes and membrane-vesicles
|
Wang, Jing |
|
|
163-164 |
C |
p. |
artikel |
238 |
Biomimetic approaches in bone tissue engineering: Integrating biological and physicomechanical strategies
|
Fernandez-Yague, Marc A. |
|
2015 |
163-164 |
C |
p. 1-29 29 p. |
artikel |
239 |
Biomimetic immunomodulation strategies for effective tissue repair and restoration
|
Villarreal-Leal, Ramiro Alejandro |
|
|
163-164 |
C |
p. |
artikel |
240 |
Biomimetic supramolecular designs for the controlled release of growth factors in bone regeneration
|
Azevedo, Helena S. |
|
2015 |
163-164 |
C |
p. 63-76 14 p. |
artikel |
241 |
Bio-mimic particles for the enhanced vaccinations: Lessons learnt from the natural traits and pathogenic invasion
|
Wu, Sihua |
|
|
163-164 |
C |
p. |
artikel |
242 |
Biopharmaceutical drug delivery and phototherapy using protein crystals
|
Zhou, Renbin |
|
|
163-164 |
C |
p. |
artikel |
243 |
Biophotonics for diagnostic detection of extracellular vesicles
|
Gualerzi, Alice |
|
|
163-164 |
C |
p. 229-249 |
artikel |
244 |
Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy
|
Zhao, Jie |
|
|
163-164 |
C |
p. |
artikel |
245 |
Bioreactor technologies to support liver function in vitro
|
Ebrahimkhani, Mohammad R. |
|
2014 |
163-164 |
C |
p. 132-157 26 p. |
artikel |
246 |
Bioresponsive drug delivery systems in intestinal inflammation: State-of-the-art and future perspectives
|
Kotla, Niranjan G. |
|
2019 |
163-164 |
C |
p. 248-266 |
artikel |
247 |
Biosafety of mesoporous silica nanoparticles; towards clinical translation
|
Lérida-Viso, Araceli |
|
|
163-164 |
C |
p. |
artikel |
248 |
Bio-synthetic materials for immunomodulation of islet transplants
|
Foster, Greg A. |
|
2017 |
163-164 |
C |
p. 266-271 |
artikel |
249 |
Bladder tissue engineering: A literature review
|
Lam Van Ba, Ornella |
|
2015 |
163-164 |
C |
p. 31-37 7 p. |
artikel |
250 |
Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins
|
Pardridge, William M. |
|
|
163-164 |
C |
p. |
artikel |
251 |
Blood-brain barrier models: Rationale for selection
|
Hanafy, Amira Sayed |
|
|
163-164 |
C |
p. |
artikel |
252 |
Blood derivatives awaken in regenerative medicine strategies to modulate wound healing
|
Mendes, Bárbara B. |
|
|
163-164 |
C |
p. 376-393 |
artikel |
253 |
Brain metastasis models: What should we aim to achieve better treatments?
|
Masmudi-Martín, M. |
|
|
163-164 |
C |
p. 79-99 |
artikel |
254 |
Branched polyesters: Preparative strategies and applications
|
d'Arcy, Richard |
|
2016 |
163-164 |
C |
p. 60-81 |
artikel |
255 |
Breaking the final barrier: Evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome
|
Mrksich, Kaitlin |
|
|
163-164 |
C |
p. |
artikel |
256 |
Breaking through the barrier: Modelling and exploiting the physical microenvironment to enhance drug transport and efficacy
|
Gładysz, Magdalena Z. |
|
|
163-164 |
C |
p. |
artikel |
257 |
Bridging the gap between testing and clinics exploring alternative pre-clinical models in melanoma research
|
Viegas, Juliana |
|
|
163-164 |
C |
p. |
artikel |
258 |
Bridging the gaps between academic research and industrial product developments of lipid-based formulations
|
Holm, René |
|
2019 |
163-164 |
C |
p. 118-127 |
artikel |
259 |
Brief update on endocytosis of nanomedicines
|
Patel, Siddharth |
|
|
163-164 |
C |
p. 90-111 |
artikel |
260 |
Bringing innovative wound care polymer materials to the market: Challenges, developments, and new trends
|
Sanjarnia, Pegah |
|
|
163-164 |
C |
p. |
artikel |
261 |
Building the design, translation and development principles of polymeric nanomedicines using the case of clinically advanced poly(lactide(glycolide))–poly(ethylene glycol) nanotechnology as a model: An industrial viewpoint
|
Lakkireddy, Harivardhan Reddy |
|
2016 |
163-164 |
C |
p. 289-332 |
artikel |
262 |
Building three-dimensional lung models for studying pharmacokinetics of inhaled drugs
|
Barros, Andreia Sofia |
|
|
163-164 |
C |
p. 386-395 |
artikel |
263 |
Burn injury: Challenges and advances in burn wound healing, infection, pain and scarring
|
Wang, Yiwei |
|
2018 |
163-164 |
C |
p. 3-17 |
artikel |
264 |
Burn wound infections microbiome and novel approaches using therapeutic microorganisms in burn wound infection control
|
Maitz, J. |
|
|
163-164 |
C |
p. |
artikel |
265 |
Caenorhabditis elegans as an emerging high throughput chronotherapeutic drug screening platform for human neurodegenerative disorders
|
Panda, Mrutyunjaya |
|
|
163-164 |
C |
p. |
artikel |
266 |
Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting
|
Rimal, Rahul |
|
|
163-164 |
C |
p. |
artikel |
267 |
Cancer nanotechnology
|
Grodzinski, Piotr |
|
2014 |
163-164 |
C |
p. 1- 1 p. |
artikel |
268 |
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
|
Bertrand, Nicolas |
|
2014 |
163-164 |
C |
p. 2-25 24 p. |
artikel |
269 |
Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments
|
Krause, Mechthild |
|
2017 |
163-164 |
C |
p. 63-73 11 p. |
artikel |
270 |
Cancer stromal targeting therapy to overcome the pitfall of EPR effect
|
Matsumura, Yasuhiro |
|
|
163-164 |
C |
p. 142-150 |
artikel |
271 |
Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies
|
Soetaert, Frederik |
|
|
163-164 |
C |
p. 65-83 |
artikel |
272 |
Candidiasis: From cutaneous to systemic, new perspectives of potential targets and therapeutic strategies
|
Lu, Hui |
|
|
163-164 |
C |
p. |
artikel |
273 |
Can microorganisms develop resistance against light based anti-infective agents?
|
Marasini, Sanjay |
|
|
163-164 |
C |
p. |
artikel |
274 |
Carbohydrate-based nanocarriers and their application to target macrophages and deliver antimicrobial agents
|
Mosaiab, Tamim |
|
|
163-164 |
C |
p. 94-129 |
artikel |
275 |
Carbon dots as multi-modal contrast agents: opportunities and open challenges for in vivo bioimaging
|
Sturabotti, Elisa |
|
|
163-164 |
C |
p. |
artikel |
276 |
Carbon dots in drug delivery and therapeutic applications
|
Singh, Hemant |
|
|
163-164 |
C |
p. |
artikel |
277 |
Cardiac fibrosis – A short review of causes and therapeutic strategies
|
Hinderer, Svenja |
|
2019 |
163-164 |
C |
p. 77-82 |
artikel |
278 |
Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies
|
Liu, Mengrui |
|
|
163-164 |
C |
p. 504-519 |
artikel |
279 |
Cardiac macrotissues-on-a-plate models for phenotypic drug screens
|
Meyer, Tim |
|
2019 |
163-164 |
C |
p. 93-100 |
artikel |
280 |
Cardiovascular drug delivery with ultrasound and microbubbles
|
Unger, Evan |
|
2014 |
163-164 |
C |
p. 110-126 17 p. |
artikel |
281 |
Careers in nanomedicine and drug delivery
|
Nance, Elizabeth |
|
|
163-164 |
C |
p. 180-189 |
artikel |
282 |
Carrier interactions with the biological barriers of the lung: Advanced in vitro models and challenges for pulmonary drug delivery
|
de Souza Carvalho, Cristiane |
|
2014 |
163-164 |
C |
p. 129-140 12 p. |
artikel |
283 |
CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs
|
Rahbarizadeh, F. |
|
2019 |
163-164 |
C |
p. 41-46 |
artikel |
284 |
Cathepsin-sensitive nanoscale drug delivery systems for cancer therapy and other diseases
|
Dheer, Divya |
|
|
163-164 |
C |
p. 130-151 |
artikel |
285 |
C. elegans in high-throughput drug discovery
|
O'Reilly, Linda P. |
|
2014 |
163-164 |
C |
p. 247-253 7 p. |
artikel |
286 |
Cell and biomaterial delivery strategies to induce immune tolerance
|
Scotland, Brianna L. |
|
|
163-164 |
C |
p. |
artikel |
287 |
Cell and tissue engineering in lymph nodes for cancer immunotherapy
|
Najibi, Alexander J. |
|
|
163-164 |
C |
p. 42-62 |
artikel |
288 |
Cell based advanced therapeutic medicinal products for bone repair: Keep it simple?
|
Leijten, J. |
|
2015 |
163-164 |
C |
p. 30-44 15 p. |
artikel |
289 |
Cell-based drug delivery systems and their in vivo fate
|
Yang, Liuxin |
|
|
163-164 |
C |
p. |
artikel |
290 |
Cell-based drug testing; this world is not flat
|
Grainger, David W. |
|
2014 |
163-164 |
C |
p. vii-xi nvt p. |
artikel |
291 |
Cell-based relay delivery strategy in biomedical applications
|
Chen, Yu |
|
|
163-164 |
C |
p. |
artikel |
292 |
Cell encapsulation: Overcoming barriers in cell transplantation in diabetes and beyond
|
Farina, Marco |
|
2019 |
163-164 |
C |
p. 92-115 |
artikel |
293 |
Cell encapsulation: ready for the next step
|
de Vos, Paul |
|
2014 |
163-164 |
C |
p. 1-2 2 p. |
artikel |
294 |
Cell-mediated enzyme prodrug cancer therapies
|
Mooney, Rachael |
|
2017 |
163-164 |
C |
p. 35-51 |
artikel |
295 |
Cell membrane-coated nanoparticles for targeting carcinogenic bacteria
|
Sun, Lei |
|
|
163-164 |
C |
p. |
artikel |
296 |
Cell-penetrating peptides in protein mimicry and cancer therapeutics
|
Zorko, Matjaž |
|
|
163-164 |
C |
p. |
artikel |
297 |
Cell permeability beyond the rule of 5
|
Matsson, Pär |
|
2016 |
163-164 |
C |
p. 42-61 20 p. |
artikel |
298 |
Cells and secretome – towards endogenous cell re-activation for cartilage repair
|
Stoddart, Martin J. |
|
2015 |
163-164 |
C |
p. 135-145 11 p. |
artikel |
299 |
Cells as advanced therapeutics: State-of-the-art, challenges, and opportunities in large scale biomanufacturing of high-quality cells for adoptive immunotherapies
|
Dwarshuis, Nate J. |
|
2017 |
163-164 |
C |
p. 222-239 |
artikel |
300 |
Cell therapy, 3D culture systems and tissue engineering for cardiac regeneration
|
Emmert, Maximilian Y. |
|
2014 |
163-164 |
C |
p. 254-269 16 p. |
artikel |
301 |
Cellular and molecular imaging of CAR-T cell-based immunotherapy
|
Liu, Longwei |
|
|
163-164 |
C |
p. |
artikel |
302 |
Cellular and subcellular interactions of graphene-based materials with cancerous and non-cancerous cells
|
Rahimi, Shadi |
|
|
163-164 |
C |
p. |
artikel |
303 |
Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology
|
Qi, Timothy |
|
|
163-164 |
C |
p. |
artikel |
304 |
Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis
|
Lin, Chien-Yu |
|
|
163-164 |
C |
p. 127-139 |
artikel |
305 |
Cellular transformers for targeted therapy
|
Chen, Chen |
|
|
163-164 |
C |
p. |
artikel |
306 |
Cellular uptake and intracellular trafficking of oligonucleotides
|
Juliano, R.L. |
|
2015 |
163-164 |
C |
p. 35-45 11 p. |
artikel |
307 |
Challenges and innovations of delivering medicines to older adults
|
Gnjidic, Danijela |
|
2018 |
163-164 |
C |
p. 97-105 |
artikel |
308 |
Challenges and innovations of drug delivery in older age
|
Khan, Muhammad Suleman |
|
2018 |
163-164 |
C |
p. 3-38 |
artikel |
309 |
Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
|
Cruz-Teran, Carlos |
|
|
163-164 |
C |
p. 100-117 |
artikel |
310 |
Challenges and opportunities for precision medicine in neurodevelopmental disorders
|
Chen, George T. |
|
|
163-164 |
C |
p. |
artikel |
311 |
Challenges and progress related to gene editing in rare skin diseases
|
Piñón Hofbauer, Josefina |
|
|
163-164 |
C |
p. |
artikel |
312 |
Challenges and solutions in polymer drug delivery for bacterial biofilm treatment: A tissue-by-tissue account
|
Kasza, Karolina |
|
|
163-164 |
C |
p. |
artikel |
313 |
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
|
Hare, Jennifer I. |
|
2017 |
163-164 |
C |
p. 25-38 14 p. |
artikel |
314 |
Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses
|
Forbes, Ben |
|
2014 |
163-164 |
C |
p. 15-33 19 p. |
artikel |
315 |
Challenges in oral drug delivery of antiretrovirals and the innovative strategies to overcome them
|
Sosnik, Alejandro |
|
|
163-164 |
C |
p. 105-120 |
artikel |
316 |
Challenges in the clinical assessment of novel tuberculosis drugs
|
Dooley, Kelly E. |
|
2016 |
163-164 |
C |
p. 116-122 7 p. |
artikel |
317 |
Challenges of fused deposition modeling 3D printing in pharmaceutical applications: Where are we now?
|
Parulski, Chloé |
|
|
163-164 |
C |
p. |
artikel |
318 |
Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers
|
Yang, Juanjuan |
|
|
163-164 |
C |
p. |
artikel |
319 |
Chaotic (bio)printing in the context of drug delivery systems
|
Alvarez, Mario Moisés |
|
|
163-164 |
C |
p. |
artikel |
320 |
Characterization and impact of peptide physicochemical properties on oral and subcutaneous delivery
|
Klepach, Alisa |
|
|
163-164 |
C |
p. |
artikel |
321 |
Characterization of dry powder inhaler performance through experimental methods
|
Ruzycki, Conor A. |
|
|
163-164 |
C |
p. |
artikel |
322 |
Chemical and structural modifications of RNAi therapeutics
|
Ku, Sook Hee |
|
2016 |
163-164 |
C |
p. 16-28 13 p. |
artikel |
323 |
Chemical degradation of proteins in the solid state with a focus on photochemical reactions
|
Mozziconacci, Olivier |
|
2015 |
163-164 |
C |
p. 2-13 12 p. |
artikel |
324 |
Chemical modification of drug molecules as strategy to reduce interactions with mucus
|
Araújo, Francisca |
|
2018 |
163-164 |
C |
p. 98-106 |
artikel |
325 |
Chemical (neo)glycosylation of biological drugs
|
Walther, Raoul |
|
|
163-164 |
C |
p. 62-76 |
artikel |
326 |
Chronopharmacology of glucocorticoids
|
Scherholz, Megerle L. |
|
|
163-164 |
C |
p. 245-261 |
artikel |
327 |
Circadian attributes of neurological and psychiatric disorders as basis for their medication chronotherapy
|
Khoshnevis, Sepideh |
|
|
163-164 |
C |
p. |
artikel |
328 |
Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy
|
Cheng, Guofeng |
|
2015 |
163-164 |
C |
p. 75-93 19 p. |
artikel |
329 |
Clinical application of microencapsulated islets: Actual prospectives on progress and challenges
|
Calafiore, Riccardo |
|
2014 |
163-164 |
C |
p. 84-92 9 p. |
artikel |
330 |
Clinical applications of pulmonary delivery of antibiotics
|
Flume, Patrick A. |
|
2015 |
163-164 |
C |
p. 1-6 6 p. |
artikel |
331 |
Clinical applications of the CellSearch platform in cancer patients
|
Riethdorf, Sabine |
|
|
163-164 |
C |
p. 102-121 |
artikel |
332 |
Clinical challenges in HIV/AIDS: Hints for advancing prevention and patient management strategies
|
Sued, Omar |
|
|
163-164 |
C |
p. 5-19 |
artikel |
333 |
Clinical delivery of circular RNA: Lessons learned from RNA drug development
|
Loan Young, Tiana |
|
|
163-164 |
C |
p. |
artikel |
334 |
Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer
|
Rachagani, Satyanarayana |
|
2015 |
163-164 |
C |
p. 16-33 18 p. |
artikel |
335 |
Clinical indications for, and the future of, circulating tumor cells
|
Moon, Dominic H. |
|
|
163-164 |
C |
p. 143-150 |
artikel |
336 |
Clinically established biodegradable long acting injectables: An industry perspective
|
Nkanga, Christian Isalomboto |
|
|
163-164 |
C |
p. 19-46 |
artikel |
337 |
Clinically-relevant and predictive cancer models for nanomedicine evaluation
|
Satchi-Fainaro, Ronit |
|
|
163-164 |
C |
p. |
artikel |
338 |
Clinical perspective on topical vaccination strategies
|
G. Popova, Petya |
|
|
163-164 |
C |
p. |
artikel |
339 |
Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings
|
Liao, Michael Z. |
|
|
163-164 |
C |
p. |
artikel |
340 |
Clinical translational barriers against nanoparticle-based imaging agents
|
Jin, Rongrong |
|
|
163-164 |
C |
p. |
artikel |
341 |
Clinical translation of advanced colonic drug delivery technologies
|
Awad, Atheer |
|
|
163-164 |
C |
p. |
artikel |
342 |
Clinical translation of immunomodulatory therapeutics
|
Nash, Amanda |
|
|
163-164 |
C |
p. |
artikel |
343 |
Clinical translation of nanomedicines: Challenges, opportunities, and keys
|
Younis, Mahmoud A. |
|
|
163-164 |
C |
p. |
artikel |
344 |
Clinical translation of stem cell based interventions for spinal cord injury — Are we there yet?
|
Chhabra, Harvinder S. |
|
2017 |
163-164 |
C |
p. 41-49 |
artikel |
345 |
Clinical utility of non-EpCAM based circulating tumor cell assays
|
Austin, R. Garland |
|
|
163-164 |
C |
p. 132-142 |
artikel |
346 |
Co association of mucus modulating agents and nanoparticles for mucosal drug delivery
|
Nordgård, Catherine Taylor |
|
2018 |
163-164 |
C |
p. 175-183 |
artikel |
347 |
Coaxing stem cells for skeletal muscle repair
|
McCullagh, Karl J.A. |
|
2015 |
163-164 |
C |
p. 198-207 10 p. |
artikel |
348 |
Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5
|
Kuminek, Gislaine |
|
2016 |
163-164 |
C |
p. 143-166 24 p. |
artikel |
349 |
Co-delivery of chemotherapeutics and proteins for synergistic therapy
|
He, Chaoliang |
|
2016 |
163-164 |
C |
p. 64-76 13 p. |
artikel |
350 |
Co-delivery of drugs and plasmid DNA for cancer therapy
|
Teo, Pei Yun |
|
2016 |
163-164 |
C |
p. 41-63 23 p. |
artikel |
351 |
Coiled coil-based therapeutics and drug delivery systems
|
Utterström, Johanna |
|
|
163-164 |
C |
p. 26-43 |
artikel |
352 |
Collagen interactions: Drug design and delivery
|
An, Bo |
|
2016 |
163-164 |
C |
p. 69-84 16 p. |
artikel |
353 |
Colloidal aspects of dispersion and digestion of self-dispersing lipid-based formulations for poorly water-soluble drugs
|
Vithani, Kapilkumar |
|
2019 |
163-164 |
C |
p. 16-34 |
artikel |
354 |
Colonizing microbiota is associated with clinical outcomes in diabetic wound healing
|
Wang, Gaofeng |
|
|
163-164 |
C |
p. |
artikel |
355 |
Combatting infectious diseases; nanotechnology as a platform for rational vaccine design
|
van Riet, Elly |
|
2014 |
163-164 |
C |
p. 28-34 7 p. |
artikel |
356 |
Combination antitumor therapy with targeted dual-nanomedicines
|
Dai, Wenbing |
|
2017 |
163-164 |
C |
p. 23-45 23 p. |
artikel |
357 |
Combination of microRNA therapeutics with small-molecule anticancer drugs: Mechanism of action and co-delivery nanocarriers
|
Dai, Xin |
|
2015 |
163-164 |
C |
p. 184-197 14 p. |
artikel |
358 |
Combinatorial drug delivery approaches for immunomodulation
|
Stewart, Joshua M. |
|
2017 |
163-164 |
C |
p. 161-174 |
artikel |
359 |
Combinatorial immunotherapy and nanoparticle mediated hyperthermia
|
Moy, Austin J. |
|
2017 |
163-164 |
C |
p. 175-183 |
artikel |
360 |
Combined use of nanocarriers and physical methods for percutaneous penetration enhancement
|
Dragicevic, Nina |
|
|
163-164 |
C |
p. 58-84 |
artikel |
361 |
Combining antigen and immunomodulators: Emerging trends in antigen-specific immunotherapy for autoimmunity
|
Northrup, Laura |
|
2016 |
163-164 |
C |
p. 86-98 13 p. |
artikel |
362 |
“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy
|
Kemp, Jessica A. |
|
2016 |
163-164 |
C |
p. 3-18 16 p. |
artikel |
363 |
Comment on: Inhaled antimicrobial therapy—Barriers to effective treatment, by J.Weers, Adv. Drug Deliv. Rev. (2014), http://dx.doi.org/ 10.1016/j.addr.2014.08.013
|
de Boer, A.H. |
|
2015 |
163-164 |
C |
p. e1-e2 nvt p. |
artikel |
364 |
Comment on: Inhaled antimicrobial therapy—Barriers to effective treatment, by J. Weers, Inhaled antimicrobial therapy — Barriers to effective treatment, Adv. Drug Deliv. Rev. (2015), http://dx.doi.org/10.1016/j.addr.2014.08.013
|
Cipolla, David |
|
2015 |
163-164 |
C |
p. e6-e7 nvt p. |
artikel |
365 |
Complement activation by drug carriers and particulate pharmaceuticals: Principles, challenges and opportunities
|
Moghimi, S. Moein |
|
|
163-164 |
C |
p. 83-95 |
artikel |
366 |
Computational investigations of hERG channel blockers: New insights and current predictive models
|
Villoutreix, Bruno O. |
|
2015 |
163-164 |
C |
p. 72-82 11 p. |
artikel |
367 |
Computational modelling of drug delivery to solid tumour: Understanding the interplay between chemotherapeutics and biological system for optimised delivery systems
|
Zhan, Wenbo |
|
2018 |
163-164 |
C |
p. 81-103 |
artikel |
368 |
Computational prediction of formulation strategies for beyond-rule-of-5 compounds
|
Bergström, Christel A.S. |
|
2016 |
163-164 |
C |
p. 6-21 16 p. |
artikel |
369 |
Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine
|
Donahue, Nathan D. |
|
|
163-164 |
C |
p. 68-96 |
artikel |
370 |
Confronting antifungal resistance, tolerance, and persistence: Advances in drug target discovery and delivery systems
|
Chen, Lei |
|
|
163-164 |
C |
p. |
artikel |
371 |
Conjugated polymer nano-systems for hyperthermia, imaging and drug delivery
|
Sarkar, Santu |
|
|
163-164 |
C |
p. 40-64 |
artikel |
372 |
Connected healthcare: Improving patient care using digital health technologies
|
Awad, Atheer |
|
|
163-164 |
C |
p. |
artikel |
373 |
Consideration of the cellular microenvironment: Physiologically relevant co-culture systems in drug discovery
|
L. Berg, Ellen |
|
2014 |
163-164 |
C |
p. 190-204 15 p. |
artikel |
374 |
Considerations for personalized neoantigen vaccination in Malignant glioma
|
Dunn, Gavin P. |
|
|
163-164 |
C |
p. |
artikel |
375 |
Contrast agents for preclinical targeted X-ray imaging
|
Li, Xiang |
|
2014 |
163-164 |
C |
p. 116-133 18 p. |
artikel |
376 |
Contribution of bioinformatics prediction in microRNA-based cancer therapeutics
|
Banwait, Jasjit K. |
|
2015 |
163-164 |
C |
p. 94-103 10 p. |
artikel |
377 |
Controlled release of drugs in electrosprayed nanoparticles for bone tissue engineering
|
Jayaraman, Praveena |
|
2015 |
163-164 |
C |
p. 77-95 19 p. |
artikel |
378 |
Controlled release technology for anti-angiogenesis treatment of posterior eye diseases: Current status and challenges
|
Lau, Chi Ming Laurence |
|
2018 |
163-164 |
C |
p. 145-161 |
artikel |
379 |
Controlling drug release with additive manufacturing-based solutions
|
Patel, Shriya K. |
|
|
163-164 |
C |
p. 369-386 |
artikel |
380 |
Controlling the function of genes and biologically active nucleic acids
|
Nishikawa, Makiya |
|
|
163-164 |
C |
p. 1 |
artikel |
381 |
Controlling timing and location in vaccines
|
Irvine, Darrell J. |
|
|
163-164 |
C |
p. 91-115 |
artikel |
382 |
Convection-enhanced delivery for brain malignancies: Technical parameters, formulation strategies and clinical perspectives
|
Parvar, Sara Jamshidi |
|
|
163-164 |
C |
p. |
artikel |
383 |
Corneal fibrosis: From in vitro models to current and upcoming drug and gene medicines
|
Trujillo Cubillo, Laura |
|
|
163-164 |
C |
p. |
artikel |
384 |
Correlation and clinical relevance of animal models for inhaled pharmaceuticals and biopharmaceuticals
|
Sécher, T. |
|
|
163-164 |
C |
p. 148-169 |
artikel |
385 |
Corrigendum to “Advanced theragnostics for the central nervous system (CNS) and neurological disorders using functional inorganic nanomaterials” [Adv. Drug Delivery Rev. 192 (2023) 114636]
|
Conklin, Brandon |
|
|
163-164 |
C |
p. |
artikel |
386 |
Corrigendum to ‘Cell-penetrating peptides in protein mimicry and cancer therapeutics’ [Advanced Drug Delivery Reviews, 180 (2022), 114044]
|
Zorko, M. |
|
|
163-164 |
C |
p. |
artikel |
387 |
Corrigendum to ‘Current state and challenges in developing oral vaccines’ [Adv. Drug Deliv. Rev. 114 (2017) 116-131]
|
Vela Ramirez, Julia E. |
|
2019 |
163-164 |
C |
p. 158 |
artikel |
388 |
Corrigendum to “Editorial: Advanced strategies to bridge the gap between inflammation and tissue regeneration” [Adv. Drug Deliv. Rev. 209 (2024) 115328]
|
Rodrigues, Márcia T. |
|
|
163-164 |
C |
p. |
artikel |
389 |
Corrigendum to “Light sheet fluorescence microscopy for monitoring drug delivery: unlocking the developmental phases of embryos” [Adv Drug Del. Rev. 218 (2025) 115520]
|
Raju, Gagan |
|
|
163-164 |
C |
p. |
artikel |
390 |
Corrigendum to “Lipid nanoparticles for targeted delivery of anticancer therapeutics: Recent advances in development of siRNA and lipoprotein-mimicking nanocarriers” [Adv. Drug Delivery Rev. 203 (2023) 115136]
|
Yaghmur, Anan |
|
|
163-164 |
C |
p. |
artikel |
391 |
Corrigendum to “Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic” [Adv. Drug Delivery Rev. 179 (2021) 114000]
|
Jain, Samagra |
|
|
163-164 |
C |
p. |
artikel |
392 |
Corrigendum to “Overcoming ocular drug delivery barriers through the use of physical forces” [Advanced Drug Delivery Reviews 126 (2018) 96–112]
|
Huang, Di |
|
2019 |
163-164 |
C |
p. 157 |
artikel |
393 |
Corrigendum to ‘Tumor-targeting peptides from combinatorial libraries’ [Adv Drug Deliv Rev.110–111 (2017) 13–37]
|
Liu, Ruiwu |
|
|
163-164 |
C |
p. 152 |
artikel |
394 |
Coupling hot melt extrusion and fused deposition modeling: Critical properties for successful performance
|
Bandari, Suresh |
|
|
163-164 |
C |
p. 52-63 |
artikel |
395 |
Covalent nano delivery systems for selective imaging and treatment of brain tumors
|
Ljubimova, Julia Y. |
|
2017 |
163-164 |
C |
p. 177-200 24 p. |
artikel |
396 |
COVID-19: An unprecedented challenge and an opportunity for change
|
Kwon, Young Jik |
|
|
163-164 |
C |
p. 48-49 |
artikel |
397 |
COVID-19 vaccines: The status and perspectives in delivery points of view
|
Chung, Jee Young |
|
|
163-164 |
C |
p. 1-25 |
artikel |
398 |
Cowpea mosaic virus nanoparticles for cancer imaging and therapy
|
Beatty, Perrin H. |
|
2019 |
163-164 |
C |
p. 130-144 |
artikel |
399 |
CRISPR/Cas bioimaging: From whole body biodistribution to single-cell dynamics
|
Kolesova, Ekaterina |
|
|
163-164 |
C |
p. |
artikel |
400 |
CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells
|
Bloomer, Hanan |
|
|
163-164 |
C |
p. |
artikel |
401 |
CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy
|
Huang, Dennis |
|
|
163-164 |
C |
p. 17-35 |
artikel |
402 |
Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments
|
Astashkina, Anna |
|
2014 |
163-164 |
C |
p. 1-18 18 p. |
artikel |
403 |
Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation
|
Afonin, Kirill A. |
|
|
163-164 |
C |
p. |
artikel |
404 |
Crossing borders in Alzheimer’s disease: A T cell’s perspective
|
van Olst, L. |
|
|
163-164 |
C |
p. |
artikel |
405 |
Crystalline mesophases: Structure, mobility, and pharmaceutical properties
|
Shalaev, Evgenyi |
|
2016 |
163-164 |
C |
p. 194-211 18 p. |
artikel |
406 |
Current advances in self-assembled nanogel delivery systems for immunotherapy
|
Tahara, Yoshiro |
|
2015 |
163-164 |
C |
p. 65-76 12 p. |
artikel |
407 |
Current and Emerging Inhaled Therapies of Repositioned Drugs
|
Cipolla, David |
|
2018 |
163-164 |
C |
p. 1-4 |
artikel |
408 |
Current and forthcoming approaches for systemic detoxification
|
Zhang, Liangfang |
|
2015 |
163-164 |
C |
p. 1-2 2 p. |
artikel |
409 |
Current and future directions of drug delivery for the treatment of mental illnesses
|
Brewster, Parker R. |
|
|
163-164 |
C |
p. |
artikel |
410 |
Current and future technological advances in transdermal gene delivery
|
Chen, Xianfeng |
|
|
163-164 |
C |
p. 85-105 |
artikel |
411 |
Current and prospective computational approaches and challenges for developing COVID-19 vaccines
|
Hwang, Woochang |
|
|
163-164 |
C |
p. 249-274 |
artikel |
412 |
Current and upcoming therapies to modulate skin scarring and fibrosis
|
Coentro, João Q. |
|
2019 |
163-164 |
C |
p. 37-59 |
artikel |
413 |
Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network
|
Vinarov, Zahari |
|
|
163-164 |
C |
p. 289-331 |
artikel |
414 |
Current developments and applications of microfluidic technology toward clinical translation of nanomedicines
|
Liu, Dongfei |
|
2018 |
163-164 |
C |
p. 54-83 |
artikel |
415 |
Current issues in optical monitoring of drug delivery via hair follicles
|
Svenskaya, Yulia I. |
|
|
163-164 |
C |
p. |
artikel |
416 |
Current preclinical small interfering RNA (siRNA)-based conjugate systems for RNA therapeutics
|
Lee, Soo Hyeon |
|
2016 |
163-164 |
C |
p. 78-92 15 p. |
artikel |
417 |
Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models
|
Chowdhury, Ekram Ahmed |
|
|
163-164 |
C |
p. 214-237 |
artikel |
418 |
Current state and challenges in developing oral vaccines
|
Vela Ramirez, Julia E. |
|
2017 |
163-164 |
C |
p. 116-131 |
artikel |
419 |
Current state of in vivo panning technologies: Designing specificity and affinity into the future of drug targeting
|
Gustafson, Heather H. |
|
2018 |
163-164 |
C |
p. 39-49 |
artikel |
420 |
Current status and challenges of model-informed drug discovery and development in China
|
Wang, Yuzhu |
|
|
163-164 |
C |
p. |
artikel |
421 |
Current strategies and opportunities to manufacture cells for modeling human lungs
|
Varma, Ratna |
|
|
163-164 |
C |
p. 90-109 |
artikel |
422 |
Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders
|
Del Grosso, Ambra |
|
|
163-164 |
C |
p. |
artikel |
423 |
Current trends in biologics delivery to restore intervertebral disc anabolism
|
Fontana, Gianluca |
|
2015 |
163-164 |
C |
p. 146-158 13 p. |
artikel |
424 |
Current trends in delivery of non-viral nucleic acid-based therapeutics for improved efficacy
|
Avci-Adali, Meltem |
|
|
163-164 |
C |
p. |
artikel |
425 |
Current understandings and clinical translation of nanomedicines for breast cancer therapy
|
Jiang, Yike |
|
|
163-164 |
C |
p. |
artikel |
426 |
Cyclodextrins applied to the treatment of lysosomal storage disorders
|
Ishitsuka, Yoichi |
|
|
163-164 |
C |
p. |
artikel |
427 |
Cytokine conjugates to elastin-like polypeptides
|
Gong, Like |
|
|
163-164 |
C |
p. |
artikel |
428 |
Cytoskeleton-modulating nanomaterials and their therapeutic potentials
|
Park, Jinwon |
|
|
163-164 |
C |
p. |
artikel |
429 |
D-amino acid-containing supramolecular nanofibers for potential cancer therapeutics
|
Wang, Huaimin |
|
2017 |
163-164 |
C |
p. 102-111 10 p. |
artikel |
430 |
Dancing with reactive oxygen species generation and elimination in nanotheranostics for disease treatment
|
Zhou, Zijian |
|
|
163-164 |
C |
p. 73-90 |
artikel |
431 |
3D — A new dimension of in vitro research
|
Hartung, Thomas |
|
2014 |
163-164 |
C |
p. vi- 1 p. |
artikel |
432 |
Dawn of lipid nanoparticles in lymph node targeting: Potential in cancer immunotherapy
|
Nakamura, Takashi |
|
|
163-164 |
C |
p. 78-88 |
artikel |
433 |
3D-Bioprinting and Micro-/Nano-Technology: Emerging Technologies in Biomedical Sciences
|
Wang, Chi-Hwa |
|
2018 |
163-164 |
C |
p. 1-2 |
artikel |
434 |
3D bioprinting for cardiovascular regeneration and pharmacology
|
Cui, Haitao |
|
2018 |
163-164 |
C |
p. 252-269 |
artikel |
435 |
3D bioprinting of functional tissue models for personalized drug screening and in vitro disease modeling
|
Ma, Xuanyi |
|
2018 |
163-164 |
C |
p. 235-251 |
artikel |
436 |
3D bioprinting of skin tissue: From pre-processing to final product evaluation
|
Yan, Wei-Cheng |
|
2018 |
163-164 |
C |
p. 270-295 |
artikel |
437 |
3D bioprinting of tissues and organs for regenerative medicine
|
Vijayavenkataraman, Sanjairaj |
|
2018 |
163-164 |
C |
p. 296-332 |
artikel |
438 |
3D cell culture systems modeling tumor growth determinants in cancer target discovery
|
Thoma, Claudio R. |
|
2014 |
163-164 |
C |
p. 29-41 13 p. |
artikel |
439 |
Decellularized myocardial matrix hydrogels: In basic research and preclinical studies
|
Wang, Raymond M. |
|
2016 |
163-164 |
C |
p. 77-82 6 p. |
artikel |
440 |
Deciphering albumin-directed drug delivery by imaging
|
Hu, Huiyu |
|
|
163-164 |
C |
p. |
artikel |
441 |
Decision support systems for personalized and participative radiation oncology
|
Lambin, Philippe |
|
2017 |
163-164 |
C |
p. 131-153 23 p. |
artikel |
442 |
Decorated bacteria and the application in drug delivery
|
Wu, Feng |
|
|
163-164 |
C |
p. |
artikel |
443 |
Decorin as a multivalent therapeutic agent against cancer
|
Neill, Thomas |
|
2016 |
163-164 |
C |
p. 174-185 12 p. |
artikel |
444 |
DectiSomes: C-type lectin receptor-targeted liposomes as pan-antifungal drugs
|
Meagher, Richard B. |
|
|
163-164 |
C |
p. |
artikel |
445 |
Deepening the understanding of the in vivo and cellular fate of nanocarriers
|
Wu, Wei |
|
|
163-164 |
C |
p. |
artikel |
446 |
Defensins: The natural peptide antibiotic
|
Gao, Xihui |
|
|
163-164 |
C |
p. |
artikel |
447 |
Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases
|
Newman, Stephen P. |
|
2018 |
163-164 |
C |
p. 5-18 |
artikel |
448 |
Delivering macrolide antibiotics to heal a broken heart – And other inflammatory conditions
|
Venditto, Vincent J. |
|
|
163-164 |
C |
p. |
artikel |
449 |
Delivering more for less: nanosized, minimal-carrier and pharmacoactive drug delivery systems
|
Etter, Emma L. |
|
|
163-164 |
C |
p. |
artikel |
450 |
Delivering on the promise of recombinant silk-inspired proteins for drug delivery
|
Gonzalez-Obeso, Constancio |
|
|
163-164 |
C |
p. |
artikel |
451 |
Delivering safer immunotherapies for cancer
|
Milling, Lauren |
|
2017 |
163-164 |
C |
p. 79-101 |
artikel |
452 |
Delivery and kinetics of immersion optical clearing agents in tissues: Optical imaging from ex vivo to in vivo
|
Yu, Tingting |
|
|
163-164 |
C |
p. |
artikel |
453 |
Delivery of antibiotics with polymeric particles
|
Xiong, Meng-Hua |
|
2014 |
163-164 |
C |
p. 63-76 14 p. |
artikel |
454 |
Delivery of biomacromolecules for therapeutic genome editing
|
Ping, Yuan |
|
|
163-164 |
C |
p. 1-2 |
artikel |
455 |
Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities
|
Au, Jessie L.-S. |
|
2016 |
163-164 |
C |
p. 280-301 22 p. |
artikel |
456 |
Delivery of cellular factors to regulate bone healing
|
Haumer, Alexander |
|
|
163-164 |
C |
p. 285-294 |
artikel |
457 |
Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer
|
Yan, Jingyue |
|
|
163-164 |
C |
p. |
artikel |
458 |
Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy
|
Song, Xiangrong |
|
|
163-164 |
C |
p. 158-180 |
artikel |
459 |
Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles
|
Luther, David C. |
|
|
163-164 |
C |
p. 188-213 |
artikel |
460 |
Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders
|
Wan, Tao |
|
|
163-164 |
C |
p. 196-216 |
artikel |
461 |
Delivery of inhalation drugs to children for asthma and other respiratory diseases
|
Kwok, Philip Chi Lip |
|
2014 |
163-164 |
C |
p. 83-88 6 p. |
artikel |
462 |
Delivery of miRNAs to the adipose organ for metabolic health
|
Kornmueller, Karin |
|
|
163-164 |
C |
p. |
artikel |
463 |
Delivery of nucleic acid based genome editing platforms via lipid nanoparticles: Clinical applications
|
Masarwy, Razan |
|
|
163-164 |
C |
p. |
artikel |
464 |
Delivery of oligonucleotides with lipid nanoparticles
|
Wang, Yuhua |
|
2015 |
163-164 |
C |
p. 68-80 13 p. |
artikel |
465 |
Delivery of STING agonists for adjuvanting subunit vaccines
|
Van Herck, Simon |
|
|
163-164 |
C |
p. |
artikel |
466 |
Delivery of synthetic mRNAs for tissue regeneration
|
Steinle, Heidrun |
|
|
163-164 |
C |
p. |
artikel |
467 |
Delivery of therapeutic oligonucleotides with cell penetrating peptides
|
Boisguérin, Prisca |
|
2015 |
163-164 |
C |
p. 52-67 16 p. |
artikel |
468 |
Delivery strategies and potential targets for siRNA in major cancer types
|
Lee, So Jin |
|
2016 |
163-164 |
C |
p. 2-15 14 p. |
artikel |
469 |
Delivery strategies for sustained drug release in the lungs
|
Loira-Pastoriza, Cristina |
|
2014 |
163-164 |
C |
p. 81-91 11 p. |
artikel |
470 |
Delivery strategies to enhance oral vaccination against enteric infections
|
Davitt, Christopher J.H. |
|
2015 |
163-164 |
C |
p. 52-69 18 p. |
artikel |
471 |
Delivery systems for the treatment of degenerated intervertebral discs
|
Blanquer, S.B.G. |
|
2015 |
163-164 |
C |
p. 172-187 16 p. |
artikel |
472 |
Delivery systems of current biologicals for the treatment of chronic cutaneous wounds and severe burns
|
Xue, Meilang |
|
|
163-164 |
C |
p. 219-241 |
artikel |
473 |
Delivery technologies for in utero gene therapy
|
Palanki, Rohan |
|
|
163-164 |
C |
p. 51-62 |
artikel |
474 |
Delivery technologies for therapeutic targeting of fibronectin in autoimmunity and fibrosis applications
|
Bonadio, Jacob D. |
|
|
163-164 |
C |
p. |
artikel |
475 |
Demystifying phytoconstituent-derived nanomedicines in their immunoregulatory and therapeutic roles in inflammatory diseases
|
Chen, Fengqian |
|
|
163-164 |
C |
p. |
artikel |
476 |
Dennis Sandell (1960–2020)
|
Asking, Lars |
|
|
163-164 |
C |
p. |
artikel |
477 |
Design control considerations for biologic-device combination products
|
Anderson, Dave |
|
2017 |
163-164 |
C |
p. 101-105 5 p. |
artikel |
478 |
Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles
|
Rijcken, Cristianne J.F. |
|
|
163-164 |
C |
p. |
artikel |
479 |
Designer bacteria as intratumoural enzyme biofactories
|
Lehouritis, Panos |
|
2017 |
163-164 |
C |
p. 8-23 |
artikel |
480 |
Designer outer membrane vesicles as immunomodulatory systems – Reprogramming bacteria for vaccine delivery
|
Gnopo, Yehou M.D. |
|
2017 |
163-164 |
C |
p. 132-142 |
artikel |
481 |
Designing electrospun fiber platforms for efficient delivery of genetic material and genome editing tools
|
Puhl, Devan L. |
|
|
163-164 |
C |
p. |
artikel |
482 |
Designing live bacterial therapeutics for cancer
|
Lee, Jaehyun |
|
|
163-164 |
C |
p. |
artikel |
483 |
Designing metal-contained enzyme mimics for prodrug activation
|
Du, Baoji |
|
2017 |
163-164 |
C |
p. 78-93 |
artikel |
484 |
Designing peptide nanoparticles for efficient brain delivery
|
Duro-Castano, Aroa |
|
|
163-164 |
C |
p. 52-77 |
artikel |
485 |
Design of disintegrable nanoassemblies to release multiple small-sized nanoparticles
|
Zhu, Dingcheng |
|
|
163-164 |
C |
p. |
artikel |
486 |
Design strategies and applications of smart optical probes in the second near-infrared window
|
Chang, Baisong |
|
|
163-164 |
C |
p. |
artikel |
487 |
Design strategies for shape-controlled magnetic iron oxide nanoparticles
|
Roca, Alejandro G. |
|
2019 |
163-164 |
C |
p. 68-104 |
artikel |
488 |
Design, synthesis and biological applications of glycopolypeptides
|
Clauss, Zachary S. |
|
|
163-164 |
C |
p. 152-167 |
artikel |
489 |
Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect
|
Liu, Zhilin |
|
|
163-164 |
C |
p. |
artikel |
490 |
Development and aging of the lymphatic vascular system
|
González-Loyola, Alejandra |
|
|
163-164 |
C |
p. 63-78 |
artikel |
491 |
Development and delivery of anti-tuberculosis drugs, vaccines and immunotherapeutics
|
Triccas, James A. |
|
2016 |
163-164 |
C |
p. 1-2 2 p. |
artikel |
492 |
Development of a virus-mimicking nanocarrier for drug delivery systems: The bio-nanocapsule
|
Somiya, Masaharu |
|
2015 |
163-164 |
C |
p. 77-89 13 p. |
artikel |
493 |
Development of extracellular vesicle-based medicinal products: A position paper of the group “Extracellular Vesicle translatiOn to clinicaL perspectiVEs – EVOLVE France”
|
Silva, Amanda K.A. |
|
|
163-164 |
C |
p. |
artikel |
494 |
Development of lipid-like materials for RNA delivery based on intracellular environment-responsive membrane destabilization and spontaneous collapse
|
Tanaka, Hiroki |
|
|
163-164 |
C |
p. 210-226 |
artikel |
495 |
Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy
|
Mekaru, Harutaka |
|
2015 |
163-164 |
C |
p. 40-49 10 p. |
artikel |
496 |
Development of nucleic acid medicines based on chemical technology
|
Kawamoto, Yusuke |
|
|
163-164 |
C |
p. |
artikel |
497 |
Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside
|
Gabizon, Alberto |
|
|
163-164 |
C |
p. 13-26 |
artikel |
498 |
Developments in extracorporeal therapy for the poisoned patient
|
Patel, Nikunjkumar |
|
2015 |
163-164 |
C |
p. 3-11 9 p. |
artikel |
499 |
Device-assisted transdermal drug delivery
|
Lee, Hyunjae |
|
|
163-164 |
C |
p. 35-45 |
artikel |
500 |
Devices for drug delivery in the gastrointestinal tract: A review of systems physically interacting with the mucosa for enhanced delivery
|
Byrne, James |
|
|
163-164 |
C |
p. |
artikel |
501 |
Devices to overcome the buccal mucosal barrier to administer therapeutic peptides
|
Malhotra, Sahil |
|
|
163-164 |
C |
p. |
artikel |
502 |
Device thrombosis and pre-clinical blood flow models for assessing antithrombogenic efficacy of drug-device combinations
|
Sukavaneshvar, Sivaprasad |
|
2017 |
163-164 |
C |
p. 24-34 11 p. |
artikel |
503 |
3D extrusion bioprinting of microbial inks for biomedical applications
|
Burns, Nicolas |
|
|
163-164 |
C |
p. |
artikel |
504 |
Diabetes associated fibrosis and drug delivery
|
Su, Qiaozhu |
|
|
163-164 |
C |
p. |
artikel |
505 |
3D in vitro models of liver fibrosis
|
van Grunsven, Leo A. |
|
2017 |
163-164 |
C |
p. 133-146 |
artikel |
506 |
Direct measurement of molecular mobility and crystallisation of amorphous pharmaceuticals using terahertz spectroscopy
|
Sibik, Juraj |
|
2016 |
163-164 |
C |
p. 147-157 11 p. |
artikel |
507 |
Diseases and conditions that impact maternal and fetal health and the potential for nanomedicine therapies
|
Nelson, Katherine M. |
|
|
163-164 |
C |
p. 425-438 |
artikel |
508 |
2D materials-based nanomedicine: From discovery to applications
|
Ouyang, Jiang |
|
|
163-164 |
C |
p. |
artikel |
509 |
2D materials for bone therapy
|
Wang, Xiangjiang |
|
|
163-164 |
C |
p. |
artikel |
510 |
DNA and RNA derivatives to optimize distribution and delivery
|
Wickstrom, Eric |
|
2015 |
163-164 |
C |
p. 25-34 10 p. |
artikel |
511 |
DNA-Based nanostructures for tumor microenvironment-responsive drug delivery
|
Li, Siqi |
|
|
163-164 |
C |
p. |
artikel |
512 |
DNA hydrogel-based gene editing and drug delivery systems
|
Mo, Fangli |
|
|
163-164 |
C |
p. 79-98 |
artikel |
513 |
Domesticating the foreign body response: Recent advances and applications
|
Veiseh, Omid |
|
|
163-164 |
C |
p. 148-161 |
artikel |
514 |
Dosage form modification and oral drug delivery in older people
|
Lau, Esther T.L. |
|
2018 |
163-164 |
C |
p. 75-84 |
artikel |
515 |
Dosing extracellular vesicles
|
Gupta, Dhanu |
|
|
163-164 |
C |
p. |
artikel |
516 |
3D printed drug delivery and testing systems — a passing fad or the future?
|
Lim, Seng Han |
|
2018 |
163-164 |
C |
p. 139-168 |
artikel |
517 |
3D printed implantable drug delivery devices for women’s health: Formulation challenges and regulatory perspective
|
Al-Litani, Karen |
|
|
163-164 |
C |
p. |
artikel |
518 |
3D printed metamaterials: properties, fabrication, and drug delivery applications
|
Singh, Hemant |
|
|
163-164 |
C |
p. |
artikel |
519 |
3D printing as a transformative tool for microneedle systems: Recent advances, manufacturing considerations and market potential
|
Economidou, Sophia N. |
|
|
163-164 |
C |
p. 60-69 |
artikel |
520 |
3D printing-enabled spatial patterning of biomimetic signals for bone tissue engineering
|
Loukelis, Konstantinos |
|
|
163-164 |
C |
p. |
artikel |
521 |
3D printing of drug delivery systems enhanced with micro/nano-technology
|
Zhu, Hui |
|
|
163-164 |
C |
p. |
artikel |
522 |
3D printing of pharmaceutical dosage forms: Recent advances and applications
|
Auel, Tobias |
|
|
163-164 |
C |
p. |
artikel |
523 |
Droplet-based 3D bioprinting for drug delivery and screening
|
Xu, Heqi |
|
|
163-164 |
C |
p. |
artikel |
524 |
Drug and cell delivery for cardiac regeneration
|
Hastings, Conn L. |
|
2015 |
163-164 |
C |
p. 85-106 22 p. |
artikel |
525 |
Drug and cell encapsulation: Alternative delivery options for the treatment of malignant brain tumors
|
Bhujbal, Swapnil V. |
|
2014 |
163-164 |
C |
p. 142-153 12 p. |
artikel |
526 |
Drug delivery across the blood-brain barrier for the treatment of pediatric brain tumors – An update
|
Power, Erica A. |
|
|
163-164 |
C |
p. |
artikel |
527 |
Drug delivery and epimorphic salamander-type mouse regeneration: A full parts and labor plan
|
Heber-Katz, Ellen |
|
|
163-164 |
C |
p. 254-261 |
artikel |
528 |
Drug delivery and tissue engineering to promote wound healing in the immunocompromised host: Current challenges and future directions
|
Tatara, Alexander M. |
|
|
163-164 |
C |
p. 319-329 |
artikel |
529 |
Drug delivery approaches for HuR-targeted therapy for lung cancer
|
Raguraman, Rajeswari |
|
|
163-164 |
C |
p. |
artikel |
530 |
Drug delivery carriers with therapeutic functions
|
Cai, Shuting S. |
|
|
163-164 |
C |
p. |
artikel |
531 |
Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics
|
Reddy, L. Harivardhan |
|
2014 |
163-164 |
C |
p. 34-57 24 p. |
artikel |
532 |
Drug delivery devices for retinal diseases
|
Kaji, Hirokazu |
|
2018 |
163-164 |
C |
p. 148-157 |
artikel |
533 |
Drug delivery for metabolism targeted cancer immunotherapy
|
Khodaei, Taravat |
|
|
163-164 |
C |
p. |
artikel |
534 |
Drug delivery progress in benign and malignant lesions of aging skin
|
Prow, Tarl W. |
|
|
163-164 |
C |
p. 1 |
artikel |
535 |
Drug delivery strategies for local immunomodulation in transplantation: Bridging the translational gap
|
Naaz, Afsana |
|
|
163-164 |
C |
p. |
artikel |
536 |
Drug delivery strategies for management of women’s health issues in the upper genital tract
|
Patel, Sravan Kumar |
|
|
163-164 |
C |
p. |
artikel |
537 |
Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity
|
Lai, Victoria |
|
|
163-164 |
C |
p. |
artikel |
538 |
Drug delivery strategies in the therapy of inflammatory bowel disease
|
Lautenschläger, Christian |
|
2014 |
163-164 |
C |
p. 58-76 19 p. |
artikel |
539 |
Drug delivery systems and materials for wound healing applications
|
Saghazadeh, Saghi |
|
|
163-164 |
C |
p. 138-166 |
artikel |
540 |
Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19
|
Brain, Danielle |
|
|
163-164 |
C |
p. |
artikel |
541 |
Drug delivery systems for programmed and on-demand release
|
Davoodi, Pooya |
|
2018 |
163-164 |
C |
p. 104-138 |
artikel |
542 |
Drug delivery systems for treating neurodevelopmental disorders
|
Barak, Boaz |
|
|
163-164 |
C |
p. |
artikel |
543 |
Drug delivery technologies for autoimmunity therapies
|
Thatte, Ajay S. |
|
|
163-164 |
C |
p. |
artikel |
544 |
Drug delivery technologies for fetal, neonatal, and maternal therapy
|
Palanki, Rohan |
|
|
163-164 |
C |
p. |
artikel |
545 |
Drug delivery to bony tissue
|
Balmayor, Elizabeth R. |
|
2015 |
163-164 |
C |
p. 1-2 2 p. |
artikel |
546 |
Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases
|
He, Wei |
|
|
163-164 |
C |
p. 15-40 |
artikel |
547 |
Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?
|
Kreuter, Jörg |
|
2014 |
163-164 |
C |
p. 2-14 13 p. |
artikel |
548 |
Drug delivery to the inflamed intestinal mucosa – targeting technologies and human cell culture models for better therapies of IBD
|
Hartwig, Olga |
|
|
163-164 |
C |
p. |
artikel |
549 |
Drug delivery to the lens for the management of cataracts
|
Thrimawithana, Thilini R. |
|
2018 |
163-164 |
C |
p. 185-194 |
artikel |
550 |
Drug delivery to the pediatric upper airway
|
Ali Akbari Ghavimi, Soheila |
|
|
163-164 |
C |
p. 168-189 |
artikel |
551 |
Drug delivery using gold nanoparticles
|
Dykman, Lev |
|
|
163-164 |
C |
p. |
artikel |
552 |
Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery
|
Borys, Nicholas |
|
|
163-164 |
C |
p. |
artikel |
553 |
Drug discovery and therapeutic delivery for the treatment of B and T cell tumors
|
Stephenson, Regan |
|
2017 |
163-164 |
C |
p. 285-300 |
artikel |
554 |
Drug discovery through stem cell-based organoid models
|
Ranga, Adrian |
|
2014 |
163-164 |
C |
p. 19-28 10 p. |
artikel |
555 |
Drug eluting antimicrobial vascular catheters: Progress and promise
|
Viola, George M. |
|
2017 |
163-164 |
C |
p. 35-47 13 p. |
artikel |
556 |
Drug eluting devices for critically ill patients: Can we apply lessons learned from the treatment of peripheral artery disease?
|
Werner, Martin |
|
2014 |
163-164 |
C |
p. 32-39 8 p. |
artikel |
557 |
Drug encapsulated polymeric microspheres for intracranial tumor therapy: A review of the literature
|
Floyd, J. Alaina |
|
2015 |
163-164 |
C |
p. 23-37 15 p. |
artikel |
558 |
Drugging the lymphatic system: An emerging opportunity for cancer immunotherapy
|
Nakamura, Takashi |
|
|
163-164 |
C |
p. |
artikel |
559 |
Drug release from in situ forming implants and advances in release testing
|
Wang, Xiaoyi |
|
|
163-164 |
C |
p. |
artikel |
560 |
Drug supersaturation during formulation digestion, including real-time analytical approaches
|
Kuentz, Martin |
|
2019 |
163-164 |
C |
p. 50-61 |
artikel |
561 |
Drug targeting to myofibroblasts: Implications for fibrosis and cancer
|
Yazdani, Saleh |
|
2017 |
163-164 |
C |
p. 101-116 |
artikel |
562 |
Drug therapies and delivery mechanisms to treat perturbed skin wound healing
|
Chin, Jiah Shin |
|
|
163-164 |
C |
p. 2-18 |
artikel |
563 |
Dry powder inhalable formulations for anti-tubercular therapy
|
Parumasivam, Thaigarajan |
|
2016 |
163-164 |
C |
p. 83-101 19 p. |
artikel |
564 |
Dry powder pharmaceutical biologics for inhalation therapy
|
Chang, Rachel Yoon Kyung |
|
|
163-164 |
C |
p. 64-79 |
artikel |
565 |
Dry powders for oral inhalation free of lactose carrier particles
|
Healy, Anne Marie |
|
2014 |
163-164 |
C |
p. 32-52 21 p. |
artikel |
566 |
3D tissue-engineered model of Ewing's sarcoma
|
Lamhamedi-Cherradi, Salah-Eddine |
|
2014 |
163-164 |
C |
p. 155-171 17 p. |
artikel |
567 |
Dual-controlled release system of drugs for bone regeneration
|
Kim, Yang-Hee |
|
2015 |
163-164 |
C |
p. 28-40 13 p. |
artikel |
568 |
Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies
|
Jang, Bora |
|
2016 |
163-164 |
C |
p. 113-133 21 p. |
artikel |
569 |
Dual-functional drug liposomes in treatment of resistant cancers
|
Mu, Li-Min |
|
2017 |
163-164 |
C |
p. 46-56 11 p. |
artikel |
570 |
Dye Doped Metal-Organic Frameworks for Enhanced Phototherapy
|
Zeng, Le |
|
|
163-164 |
C |
p. |
artikel |
571 |
Dynamic nano-assemblies based on two-dimensional inorganic nanoparticles: Construction and preclinical demonstration
|
Sun, Luyao |
|
|
163-164 |
C |
p. |
artikel |
572 |
Dynamic nanoassemblies for imaging and therapy of neurological disorders
|
Zhang, Lingxiao |
|
|
163-164 |
C |
p. |
artikel |
573 |
Dynamic nanoassemblies of nanomaterials for cancer photomedicine
|
Jeong, Hayoon |
|
|
163-164 |
C |
p. |
artikel |
574 |
Dynamic nanoassembly-based drug delivery system (DNDDS): Learning from nature
|
Hu, Xi |
|
|
163-164 |
C |
p. |
artikel |
575 |
Dynamic reciprocity in cell–scaffold interactions
|
Mauney, Joshua R. |
|
2015 |
163-164 |
C |
p. 77-85 9 p. |
artikel |
576 |
ECM and ECM-like materials — Biomaterials for applications in regenerative medicine and cancer therapy
|
Hinderer, Svenja |
|
2016 |
163-164 |
C |
p. 260-269 10 p. |
artikel |
577 |
Editorial
|
Hou, Tingjun |
|
2015 |
163-164 |
C |
p. 1- 1 p. |
artikel |
578 |
Editorial: Advanced Liposome Research
|
Harashima, Hideyoshi |
|
|
163-164 |
C |
p. 1 |
artikel |
579 |
Editorial: Advanced strategies to bridge the gap between inflammation and tissue regeneration
|
Rodrigues, Márcia T. |
|
|
163-164 |
C |
p. |
artikel |
580 |
Editorial: Biomedical Engineering Approaches for HIV/AIDS Prophylaxis, Diagnostics and Therapy
|
Neves, José das |
|
|
163-164 |
C |
p. 1-4 |
artikel |
581 |
Editorial Board
|
|
|
2014 |
163-164 |
C |
p. ii- 1 p. |
artikel |
582 |
Editorial Board
|
|
|
2014 |
163-164 |
C |
p. ii- 1 p. |
artikel |
583 |
Editorial Board
|
|
|
2014 |
163-164 |
C |
p. ii- 1 p. |
artikel |
584 |
Editorial Board
|
|
|
2014 |
163-164 |
C |
p. ii- 1 p. |
artikel |
585 |
Editorial Board
|
|
|
2014 |
163-164 |
C |
p. ii- 1 p. |
artikel |
586 |
Editorial Board
|
|
|
2015 |
163-164 |
C |
p. ii- 1 p. |
artikel |
587 |
Editorial Board
|
|
|
2016 |
163-164 |
C |
p. ii- 1 p. |
artikel |
588 |
Editorial Board
|
|
|
2016 |
163-164 |
C |
p. ii- 1 p. |
artikel |
589 |
Editorial Board
|
|
|
2015 |
163-164 |
C |
p. ii- 1 p. |
artikel |
590 |
Editorial Board
|
|
|
2016 |
163-164 |
C |
p. ii- 1 p. |
artikel |
591 |
Editorial Board
|
|
|
2017 |
163-164 |
C |
p. ii- 1 p. |
artikel |
592 |
Editorial Board
|
|
|
2015 |
163-164 |
C |
p. ii- 1 p. |
artikel |
593 |
Editorial Board
|
|
|
2014 |
163-164 |
C |
p. ii- 1 p. |
artikel |
594 |
Editorial Board
|
|
|
2015 |
163-164 |
C |
p. ii- 1 p. |
artikel |
595 |
Editorial Board
|
|
|
2015 |
163-164 |
C |
p. ii- 1 p. |
artikel |
596 |
Editorial Board
|
|
|
2015 |
163-164 |
C |
p. ii- 1 p. |
artikel |
597 |
Editorial Board
|
|
|
2014 |
163-164 |
C |
p. ii- 1 p. |
artikel |
598 |
Editorial Board
|
|
|
2017 |
163-164 |
C |
p. ii- 1 p. |
artikel |
599 |
Editorial Board
|
|
|
2017 |
163-164 |
C |
p. ii- 1 p. |
artikel |
600 |
Editorial Board
|
|
|
2017 |
163-164 |
C |
p. ii- 1 p. |
artikel |
601 |
Editorial Board
|
|
|
2017 |
163-164 |
C |
p. ii- 1 p. |
artikel |
602 |
Editorial Board
|
|
|
2017 |
163-164 |
C |
p. ii- 1 p. |
artikel |
603 |
Editorial Board
|
|
|
2016 |
163-164 |
C |
p. ii- 1 p. |
artikel |
604 |
Editorial Board
|
|
|
2017 |
163-164 |
C |
p. ii |
artikel |
605 |
Editorial Board
|
|
|
2017 |
163-164 |
C |
p. ii |
artikel |
606 |
Editorial Board
|
|
|
2018 |
163-164 |
C |
p. ii |
artikel |
607 |
Editorial Board
|
|
|
2018 |
163-164 |
C |
p. ii |
artikel |
608 |
Editorial Board
|
|
|
2016 |
163-164 |
C |
p. ii |
artikel |
609 |
Editorial Board
|
|
|
2017 |
163-164 |
C |
p. ii |
artikel |
610 |
Editorial Board
|
|
|
2017 |
163-164 |
C |
p. ii |
artikel |
611 |
Editorial Board
|
|
|
2017 |
163-164 |
C |
p. ii- 1 p. |
artikel |
612 |
Editorial Board
|
|
|
2017 |
163-164 |
C |
p. ii |
artikel |
613 |
Editorial Board
|
|
|
2015 |
163-164 |
C |
p. ii- 1 p. |
artikel |
614 |
Editorial Board
|
|
|
2015 |
163-164 |
C |
p. ii- 1 p. |
artikel |
615 |
Editorial Board
|
|
|
2015 |
163-164 |
C |
p. ii- 1 p. |
artikel |
616 |
Editorial Board
|
|
|
2014 |
163-164 |
C |
p. ii- 1 p. |
artikel |
617 |
Editorial Board
|
|
|
2014 |
163-164 |
C |
p. ii- 1 p. |
artikel |
618 |
Editorial Board
|
|
|
2015 |
163-164 |
C |
p. ii- 1 p. |
artikel |
619 |
Editorial Board
|
|
|
2015 |
163-164 |
C |
p. ii- 1 p. |
artikel |
620 |
Editorial Board
|
|
|
2015 |
163-164 |
C |
p. ii- 1 p. |
artikel |
621 |
Editorial Board
|
|
|
2014 |
163-164 |
C |
p. ii- 1 p. |
artikel |
622 |
Editorial Board
|
|
|
2015 |
163-164 |
C |
p. ii- 1 p. |
artikel |
623 |
Editorial Board
|
|
|
2014 |
163-164 |
C |
p. ii- 1 p. |
artikel |
624 |
Editorial Board
|
|
|
2016 |
163-164 |
C |
p. ii- 1 p. |
artikel |
625 |
Editorial Board
|
|
|
2016 |
163-164 |
C |
p. ii- 1 p. |
artikel |
626 |
Editorial Board
|
|
|
2015 |
163-164 |
C |
p. ii- 1 p. |
artikel |
627 |
Editorial Board
|
|
|
2016 |
163-164 |
C |
p. ii- 1 p. |
artikel |
628 |
Editorial Board
|
|
|
2018 |
163-164 |
C |
p. ii |
artikel |
629 |
Editorial Board
|
|
|
2018 |
163-164 |
C |
p. ii |
artikel |
630 |
Editorial Board
|
|
|
2018 |
163-164 |
C |
p. ii |
artikel |
631 |
Editorial Board
|
|
|
2018 |
163-164 |
C |
p. ii |
artikel |
632 |
Editorial Board
|
|
|
2018 |
163-164 |
C |
p. ii |
artikel |
633 |
Editorial board
|
|
|
2019 |
163-164 |
C |
p. ii |
artikel |
634 |
Editorial Board
|
|
|
2019 |
163-164 |
C |
p. ii |
artikel |
635 |
Editorial Board
|
|
|
2018 |
163-164 |
C |
p. ii |
artikel |
636 |
Editorial Board
|
|
|
2018 |
163-164 |
C |
p. ii |
artikel |
637 |
Editorial Board
|
|
|
2019 |
163-164 |
C |
p. ii |
artikel |
638 |
Editorial Board
|
|
|
2019 |
163-164 |
C |
p. ii |
artikel |
639 |
Editorial Board
|
|
|
2019 |
163-164 |
C |
p. ii |
artikel |
640 |
Editorial Board
|
|
|
|
163-164 |
C |
p. ii |
artikel |
641 |
Editorial Board
|
|
|
|
163-164 |
C |
p. ii |
artikel |
642 |
Editorial Board
|
|
|
2019 |
163-164 |
C |
p. ii |
artikel |
643 |
Editorial Board
|
|
|
2019 |
163-164 |
C |
p. ii |
artikel |
644 |
Editorial Board
|
|
|
|
163-164 |
C |
p. ii |
artikel |
645 |
Editorial Board
|
|
|
|
163-164 |
C |
p. ii |
artikel |
646 |
Editorial Board
|
|
|
|
163-164 |
C |
p. ii |
artikel |
647 |
Editorial Board
|
|
|
|
163-164 |
C |
p. ii |
artikel |
648 |
Editorial Board
|
|
|
|
163-164 |
C |
p. ii |
artikel |
649 |
Editorial Board
|
|
|
|
163-164 |
C |
p. ii |
artikel |
650 |
Editorial board
|
|
|
|
163-164 |
C |
p. ii |
artikel |
651 |
Editorial Board
|
|
|
|
163-164 |
C |
p. ii |
artikel |
652 |
Editorial Board
|
|
|
|
163-164 |
C |
p. ii |
artikel |
653 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
654 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
655 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
656 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
657 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
658 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
659 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
660 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
661 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
662 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
663 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
664 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
665 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
666 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
667 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
668 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
669 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
670 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
671 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
672 |
Editorial Board
|
|
|
|
163-164 |
C |
p. |
artikel |
673 |
Editorial Board Members
|
|
|
2017 |
163-164 |
C |
p. ii- 1 p. |
artikel |
674 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
675 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
676 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
677 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
678 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
679 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
680 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
681 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
682 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
683 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
684 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
685 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
686 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
687 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
688 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
689 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
690 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
691 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
692 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
693 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
694 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
695 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
696 |
Editorial board members
|
|
|
2017 |
163-164 |
C |
p. ii |
artikel |
697 |
Editorial board members
|
|
|
2018 |
163-164 |
C |
p. ii |
artikel |
698 |
Editorial board members
|
|
|
2018 |
163-164 |
C |
p. ii |
artikel |
699 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
700 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
701 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
702 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
703 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
704 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
705 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
706 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
707 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
708 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
709 |
Editorial board members
|
|
|
|
163-164 |
C |
p. ii |
artikel |
710 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
711 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
712 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
713 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
714 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
715 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
716 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
717 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
718 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
719 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
720 |
Editorial board members
|
|
|
|
163-164 |
C |
p. |
artikel |
721 |
Editorial: Drug delivery in older people – unique challenges and important opportunities
|
McLachlan, Andrew J. |
|
2018 |
163-164 |
C |
p. 1-2 |
artikel |
722 |
Editorial: Drug Nanoparticles and Nano-Cocrystals: From Production and Characterization to Clinical Translation
|
Sosnik, Alejandro |
|
2018 |
163-164 |
C |
p. 1-2 |
artikel |
723 |
Editorial Editorial
|
|
|
2014 |
163-164 |
C |
p. ii- 1 p. |
artikel |
724 |
Editorial: Editors’ Collection 2016
|
Ghandehari, Hamidreza |
|
2017 |
163-164 |
C |
p. 1- 1 p. |
artikel |
725 |
Editorial/Preface
|
Ling, Daishun |
|
|
163-164 |
C |
p. |
artikel |
726 |
Editorial: Subcellular organelle-targeting of nanomaterials for enhancing therapeutic effectiveness
|
Youn, Yu Seok |
|
|
163-164 |
C |
p. |
artikel |
727 |
Editorial: Super-resolution imaging of sub-cellular dynamics of drug molecules
|
Chen, Qixin |
|
|
163-164 |
C |
p. |
artikel |
728 |
Editorial: Tissue engineering of the heart
|
Radisic, Milica |
|
2016 |
163-164 |
C |
p. 1-2 2 p. |
artikel |
729 |
Editorial to ‘Biological Barriers to Drug Delivery’
|
Kumar, M.N.V. Ravi |
|
|
163-164 |
C |
p. |
artikel |
730 |
Editorial to “Journey into the immunological properties of engineered nanomaterials: There and back again”
|
Dobrovolskaia, Marina A. |
|
|
163-164 |
C |
p. |
artikel |
731 |
Editorial to “Molecular engineering of biomaterials programmed to operate in living systems”
|
Afonin, Kirill A. |
|
|
163-164 |
C |
p. |
artikel |
732 |
Effective use of transdermal drug delivery in children
|
Delgado-Charro, M. Begoña |
|
2014 |
163-164 |
C |
p. 63-82 20 p. |
artikel |
733 |
Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers
|
Zhao, Zongmin |
|
|
163-164 |
C |
p. 3-21 |
artikel |
734 |
Effects of Klotho on fibrosis and cancer: A renal focus on mechanisms and therapeutic strategies
|
Mencke, Rik |
|
2017 |
163-164 |
C |
p. 85-100 |
artikel |
735 |
Effects of nanoparticle deformability on multiscale biotransport
|
Gadalla, Hytham H. |
|
|
163-164 |
C |
p. |
artikel |
736 |
Efficacy and safety concerns over the use of mucus modulating agents for drug delivery using nanoscale systems
|
Chater, Peter I. |
|
2018 |
163-164 |
C |
p. 184-192 |
artikel |
737 |
Elastin-like polypeptides in drug delivery
|
Rodríguez-Cabello, José Carlos |
|
2016 |
163-164 |
C |
p. 85-100 16 p. |
artikel |
738 |
Electrical and mechanical stimulation of cardiac cells and tissue constructs
|
Stoppel, Whitney L. |
|
2016 |
163-164 |
C |
p. 135-155 21 p. |
artikel |
739 |
Electrically conductive nanomaterials for cardiac tissue engineering
|
Ashtari, Khadijeh |
|
|
163-164 |
C |
p. 162-179 |
artikel |
740 |
Electric field-responsive nanoparticles and electric fields: physical, chemical, biological mechanisms and therapeutic prospects
|
Kolosnjaj-Tabi, Jelena |
|
2019 |
163-164 |
C |
p. 56-67 |
artikel |
741 |
Electroactive biomaterials: Vehicles for controlled delivery of therapeutic agents for drug delivery and tissue regeneration
|
Tandon, Biranche |
|
|
163-164 |
C |
p. 148-168 |
artikel |
742 |
Electroactive material-based biosensors for detection and drug delivery
|
Olvera, Dinorath |
|
|
163-164 |
C |
p. 396-424 |
artikel |
743 |
Electrohydrodynamic atomisation driven design and engineering of opportunistic particulate systems for applications in drug delivery, therapeutics and pharmaceutics
|
Ali, Amna |
|
|
163-164 |
C |
p. |
artikel |
744 |
Electrohydrodynamic atomization and spray-drying for the production of pure drug nanocrystals and co-crystals
|
Sverdlov Arzi, Roni |
|
2018 |
163-164 |
C |
p. 79-100 |
artikel |
745 |
Electrospinning: An enabling nanotechnology platform for drug delivery and regenerative medicine
|
Chen, Shixuan |
|
2018 |
163-164 |
C |
p. 188-213 |
artikel |
746 |
Elongated self-assembled nanocarriers: From molecular organization to therapeutic applications
|
Mougin, Julie |
|
|
163-164 |
C |
p. 127-147 |
artikel |
747 |
Emergence of multidrug-resistant bacteria: important role of macromolecules and drug delivery systems
|
Yang, Yi Yan |
|
2014 |
163-164 |
C |
p. 1-2 2 p. |
artikel |
748 |
Emerging aerosol drug delivery strategies: From bench to clinic
|
Rubin, Bruce K. |
|
2014 |
163-164 |
C |
p. 141-148 8 p. |
artikel |
749 |
Emerging antibiotic alternatives: From antimicrobial peptides to bacteriophage therapies
|
Leung, Sharon Shui Yee |
|
|
163-164 |
C |
p. |
artikel |
750 |
Emerging delivery approaches for targeted pulmonary fibrosis treatment
|
Diwan, Rimpy |
|
|
163-164 |
C |
p. |
artikel |
751 |
Emerging 3D printing technologies for drug delivery devices: Current status and future perspective
|
Wang, Jiawei |
|
|
163-164 |
C |
p. 294-316 |
artikel |
752 |
Emerging drug delivery systems with traditional routes – A roadmap to chronic inflammatory diseases
|
Min, Kiyoon |
|
|
163-164 |
C |
p. |
artikel |
753 |
Emerging hyperthermia applications for pediatric oncology
|
Tydings, Caitlin |
|
|
163-164 |
C |
p. 157-167 |
artikel |
754 |
Emerging inhalation aerosol devices and strategies: Where are we headed?
|
Zhou, Qi (Tony) |
|
2014 |
163-164 |
C |
p. 3-17 15 p. |
artikel |
755 |
Emerging innate biological properties of nano-drug delivery systems: A focus on PAMAM dendrimers and their clinical potential
|
Kheraldine, Hadeel |
|
|
163-164 |
C |
p. |
artikel |
756 |
Emerging Nanomedical Solutions for Angiogenesis Regulation
|
Blau, Rachel |
|
2017 |
163-164 |
C |
p. 1-2 |
artikel |
757 |
Emerging opportunities in bioconjugates of Elastin-like polypeptides with synthetic or natural polymers
|
Garanger, Elisabeth |
|
|
163-164 |
C |
p. |
artikel |
758 |
Emerging plasmonic nanoparticles and their assemblies for cancer radiotherapy
|
Wu, Ying |
|
|
163-164 |
C |
p. |
artikel |
759 |
Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors
|
Askoxylakis, Vasileios |
|
2017 |
163-164 |
C |
p. 159-174 |
artikel |
760 |
Emerging strategies for nanomedicine in autoimmunity
|
Thatte, Ajay S. |
|
|
163-164 |
C |
p. |
artikel |
761 |
Emerging strategies in developing multifunctional nanomaterials for cancer nanotheranostics
|
Ang, Melgious Jin Yan |
|
|
163-164 |
C |
p. |
artikel |
762 |
Emerging strategies of engineering retinal organoids and organoid-on-a-chip in modeling intraocular drug delivery: Current progress and future perspectives
|
Yu, Jiaheng |
|
|
163-164 |
C |
p. |
artikel |
763 |
Emerging strategies to bypass transplant rejection via biomaterial-assisted immunoengineering: Insights from islets and beyond
|
Abbaszadeh, Samin |
|
|
163-164 |
C |
p. |
artikel |
764 |
Emerging targeted drug delivery strategies toward ovarian cancer
|
Wang, Zhe |
|
|
163-164 |
C |
p. |
artikel |
765 |
Emerging technologies for monitoring drug-resistant tuberculosis at the point-of-care
|
Mani, Vigneshwaran |
|
2014 |
163-164 |
C |
p. 105-117 13 p. |
artikel |
766 |
Emerging tools and targets for immune engineering and modulation
|
Rodell, Christopher B. |
|
|
163-164 |
C |
p. |
artikel |
767 |
Emerging translational approaches for brain cancer therapeutics
|
Kim, Anthony J. |
|
|
163-164 |
C |
p. |
artikel |
768 |
Emerging trends in inhaled drug delivery
|
Hickey, Anthony J. |
|
|
163-164 |
C |
p. 63-70 |
artikel |
769 |
Emerging Voices in Drug Delivery – Breaking Barriers (Issue 1)
|
Nguyen, Juliane |
|
|
163-164 |
C |
p. |
artikel |
770 |
Emerging Voices in Drug Delivery – Harnessing and Modulating Complex Biological Systems (Issue 2)
|
Owen, Shawn C. |
|
|
163-164 |
C |
p. |
artikel |
771 |
Enabling biodegradable functional biomaterials for the management of neurological disorders
|
Shan, Dingying |
|
|
163-164 |
C |
p. 219-238 |
artikel |
772 |
Enabling technologies for in situ biomanufacturing using probiotic yeast
|
Parker, William |
|
|
163-164 |
C |
p. |
artikel |
773 |
Encapsulated cell therapy for neurodegenerative diseases: From promise to product
|
Emerich, Dwaine F. |
|
2014 |
163-164 |
C |
p. 131-141 11 p. |
artikel |
774 |
Encapsulated islets for diabetes therapy: History, current progress, and critical issues requiring solution
|
Scharp, David W. |
|
2014 |
163-164 |
C |
p. 35-73 39 p. |
artikel |
775 |
Encapsulation and immune protection for type 1 diabetes cell therapy
|
Kioulaphides, Sophia |
|
|
163-164 |
C |
p. |
artikel |
776 |
Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers
|
Poluzzi, Chiara |
|
2016 |
163-164 |
C |
p. 156-173 18 p. |
artikel |
777 |
Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy
|
Long, Qiong |
|
|
163-164 |
C |
p. |
artikel |
778 |
Engineered cell and tissue models of pulmonary fibrosis
|
Sundarakrishnan, Aswin |
|
|
163-164 |
C |
p. 78-94 |
artikel |
779 |
Engineered delivery strategies for enhanced control of growth factor activities in wound healing
|
Niu, Yiming |
|
2019 |
163-164 |
C |
p. 190-208 |
artikel |
780 |
Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies
|
Tzatzalos, Evangeline |
|
2016 |
163-164 |
C |
p. 234-244 11 p. |
artikel |
781 |
Engineered microbial systems for advanced drug delivery
|
Shen, Haosheng |
|
|
163-164 |
C |
p. |
artikel |
782 |
Engineered microenvironments provide new insights into ovarian and prostate cancer progression and drug responses
|
Loessner, Daniela |
|
2014 |
163-164 |
C |
p. 193-213 21 p. |
artikel |
783 |
Engineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain
|
Wu, Jason R. |
|
|
163-164 |
C |
p. |
artikel |
784 |
Engineered nanoparticles mimicking cell membranes for toxin neutralization
|
Fang, Ronnie H. |
|
2015 |
163-164 |
C |
p. 69-80 12 p. |
artikel |
785 |
Engineered organoids for biomedical applications
|
Roberto de Barros, Natan |
|
|
163-164 |
C |
p. |
artikel |
786 |
Engineered tissues and strategies to overcome challenges in drug development
|
Khalil, Andrew S. |
|
|
163-164 |
C |
p. 116-139 |
artikel |
787 |
Engineering and loading therapeutic extracellular vesicles for clinical translation: A data reporting frame for comparability
|
Piffoux, Max |
|
|
163-164 |
C |
p. |
artikel |
788 |
Engineering antigen-presenting cells for immunotherapy of autoimmunity
|
Smith, Clinton T. |
|
|
163-164 |
C |
p. |
artikel |
789 |
Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer
|
Gao, Jin |
|
|
163-164 |
C |
p. |
artikel |
790 |
Engineering broadly neutralizing antibodies for HIV prevention and therapy
|
Hua, Casey K. |
|
|
163-164 |
C |
p. 157-173 |
artikel |
791 |
Engineering cells for precision drug delivery: New advances, clinical translation, and emerging strategies
|
Chao, Chih-Jia |
|
|
163-164 |
C |
p. |
artikel |
792 |
Engineering challenges for brain tumor immunotherapy
|
Lyon, Johnathan G. |
|
2017 |
163-164 |
C |
p. 19-32 |
artikel |
793 |
Engineering complexity in human tissue models of cancer
|
Ronaldson-Bouchard, Kacey |
|
|
163-164 |
C |
p. |
artikel |
794 |
Engineering interferons and interleukins for cancer immunotherapy
|
Holder, Patrick G. |
|
|
163-164 |
C |
p. |
artikel |
795 |
Engineering in vitro immune-competent tissue models for testing and evaluation of therapeutics
|
Hammel, Jennifer H. |
|
|
163-164 |
C |
p. |
artikel |
796 |
Engineering in vitro models of hepatofibrogenesis
|
Mazza, Giuseppe |
|
2017 |
163-164 |
C |
p. 147-157 |
artikel |
797 |
Engineering lymphocytes with RNAi
|
Ramishetti, Srinivas |
|
2019 |
163-164 |
C |
p. 55-66 |
artikel |
798 |
Engineering macromolecular nanocarriers for local delivery of gaseous signaling molecules
|
Hu, Jinming |
|
|
163-164 |
C |
p. |
artikel |
799 |
Engineering metabolism to modulate immunity
|
Kapnick, Senta M. |
|
|
163-164 |
C |
p. |
artikel |
800 |
Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties
|
Wu, Lei |
|
2018 |
163-164 |
C |
p. 150-163 |
artikel |
801 |
Engineering nanoparticle toolkits for mRNA delivery
|
Sun, Bing |
|
|
163-164 |
C |
p. |
artikel |
802 |
Engineering nanosystems to overcome barriers to cancer diagnosis and treatment
|
Alhaj-Suliman, Suhaila O. |
|
|
163-164 |
C |
p. |
artikel |
803 |
Engineering of stimuli-responsive self-assembled biomimetic nanoparticles
|
Krishnan, Nishta |
|
|
163-164 |
C |
p. |
artikel |
804 |
Engineering of tumor microenvironments
|
Hutmacher, Dietmar W. |
|
2014 |
163-164 |
C |
p. 1-2 2 p. |
artikel |
805 |
Engineering self-assembled materials to study and direct immune function
|
Tostanoski, Lisa H. |
|
2017 |
163-164 |
C |
p. 60-78 |
artikel |
806 |
Engineering strategies to capture the biological and biophysical tumor microenvironment in vitro
|
Tan, Matthew L. |
|
|
163-164 |
C |
p. |
artikel |
807 |
Engineering strategies to mimic the glioblastoma microenvironment
|
Rape, Andrew |
|
2014 |
163-164 |
C |
p. 172-183 12 p. |
artikel |
808 |
Engineering stromal heterogeneity in cancer
|
Tang, Leon Jia Wei |
|
|
163-164 |
C |
p. |
artikel |
809 |
Engineering the drug carrier biointerface to overcome biological barriers to drug delivery
|
Finbloom, Joel A. |
|
|
163-164 |
C |
p. 89-108 |
artikel |
810 |
Engineering the right formulation for enhanced drug delivery
|
Ke, Wei-Ren |
|
|
163-164 |
C |
p. |
artikel |
811 |
Engineering Xenopus embryos for phenotypic drug discovery screening
|
Schmitt, Stefan M. |
|
2014 |
163-164 |
C |
p. 225-246 22 p. |
artikel |
812 |
Enhanced antimicrobial activity through the combination of antimicrobial photodynamic therapy and low-frequency ultrasonic irradiation
|
Wang, Ying |
|
|
163-164 |
C |
p. |
artikel |
813 |
Enhancing organoid technology with carbon-based nanomaterial biosensors: Advancements, challenges, and future directions
|
Rezaei, Zahra |
|
|
163-164 |
C |
p. |
artikel |
814 |
Enhancing patient-level clinical data access to promote evidence-based practice and incentivize therapeutic innovation
|
Fortunato, Alice |
|
2018 |
163-164 |
C |
p. 97-104 |
artikel |
815 |
Enhancing the persistence of engineered biotherapeutics in the gut: Adhesion, glycan metabolism, and environmental resistance
|
Lee, Yujin |
|
|
163-164 |
C |
p. |
artikel |
816 |
Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors
|
Ye, Tong |
|
|
163-164 |
C |
p. |
artikel |
817 |
Enhancing the therapeutic use of biofilm-dispersing enzymes with smart drug delivery systems
|
Thorn, Chelsea R. |
|
|
163-164 |
C |
p. |
artikel |
818 |
Ensuring confidence in predictions: A scheme to assess the scientific validity of in silico models
|
Hewitt, Mark |
|
2015 |
163-164 |
C |
p. 101-111 11 p. |
artikel |
819 |
Enzyme decorated drug carriers: Targeted swords to cleave and overcome the mucus barrier
|
Menzel, Claudia |
|
2018 |
163-164 |
C |
p. 164-174 |
artikel |
820 |
Enzyme prodrug therapies and therapeutic enzymes
|
Städler, Brigitte |
|
2017 |
163-164 |
C |
p. 1 |
artikel |
821 |
Enzymes as key features in therapeutic cell mimicry
|
Itel, Fabian |
|
2017 |
163-164 |
C |
p. 94-108 |
artikel |
822 |
Enzyme therapeutics for systemic detoxification
|
Liu, Yang |
|
2015 |
163-164 |
C |
p. 24-39 16 p. |
artikel |
823 |
Epigenetic reprogramming in liver fibrosis and cancer
|
Wilson, Caroline L. |
|
2017 |
163-164 |
C |
p. 124-132 |
artikel |
824 |
Erratum to “Can microorganisms develop resistance against light based anti-infective agents?” [Adv. Drug Delivery Rev. 175 (2021) 113822]
|
Marasini, Sanjay |
|
|
163-164 |
C |
p. |
artikel |
825 |
Erratum to ‘Silk fibroin for skin injury repair: Where do things stand?’. [Advanced Drug Delivery Reviews 153 (2020) 28-53]
|
Gholipourmalekabadi, Mazaher |
|
|
163-164 |
C |
p. 190-196 |
artikel |
826 |
Evaluation of transporters in drug development: Current status and contemporary issues
|
Lee, Sue-Chih |
|
2017 |
163-164 |
C |
p. 100-118 19 p. |
artikel |
827 |
Evolution of nanomedicine formulations for targeted delivery and controlled release
|
Puri, Sanyogitta |
|
|
163-164 |
C |
p. |
artikel |
828 |
Evolution of nanomedicines for the treatment of autoimmune disease: From vehicles for drug delivery to inducers of bystander immunoregulation
|
Yang, Yang |
|
|
163-164 |
C |
p. |
artikel |
829 |
Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
|
Bhagchandani, Sachin |
|
|
163-164 |
C |
p. |
artikel |
830 |
Exon skipping therapy for Duchenne muscular dystrophy
|
Kole, Ryszard |
|
2015 |
163-164 |
C |
p. 104-107 4 p. |
artikel |
831 |
Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders
|
Lu, Biao |
|
|
163-164 |
C |
p. |
artikel |
832 |
Exosomes and GPI-anchored proteins: Judicious pairs for investigating biomarkers from body fluids
|
Vidal, Michel |
|
|
163-164 |
C |
p. 110-123 |
artikel |
833 |
Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs)
|
Ke, Weina |
|
|
163-164 |
C |
p. |
artikel |
834 |
Expanding the chemical repertoire of protein-based polymers for drug-delivery applications
|
Gueta, Osher |
|
|
163-164 |
C |
p. |
artikel |
835 |
Experimental cocrystal screening and solution based scale-up cocrystallization methods
|
Malamatari, Maria |
|
2017 |
163-164 |
C |
p. 162-177 16 p. |
artikel |
836 |
Experimental models of bone metastasis: Opportunities for the study of cancer dormancy
|
Chong Seow Khoon, Mark |
|
2015 |
163-164 |
C |
p. 141-150 10 p. |
artikel |
837 |
Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges
|
Maisel, Katharina |
|
2017 |
163-164 |
C |
p. 43-59 |
artikel |
838 |
Exploiting nanoscale cooperativity for precision medicine
|
Wilhelm, Jonathan |
|
|
163-164 |
C |
p. 63-72 |
artikel |
839 |
Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments
|
McGivern, Jered V. |
|
2014 |
163-164 |
C |
p. 170-178 9 p. |
artikel |
840 |
Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers
|
Fang, Jun |
|
|
163-164 |
C |
p. 142-160 |
artikel |
841 |
Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy
|
Figueroa-Espada, Christian G. |
|
|
163-164 |
C |
p. 244-261 |
artikel |
842 |
Exploring interactions between extracellular vesicles and cells for innovative drug delivery system design
|
Kooijmans, Sander A.A. |
|
|
163-164 |
C |
p. 252-278 |
artikel |
843 |
Exploring the potential of cell-derived vesicles for transient delivery of gene editing payloads
|
Leandro, Kevin |
|
|
163-164 |
C |
p. |
artikel |
844 |
Expression, activity and pharmacokinetic impact of ocular transporters
|
Vellonen, Kati-Sisko |
|
2018 |
163-164 |
C |
p. 3-22 |
artikel |
845 |
External physical and biochemical stimulation to enhance skeletal muscle bioengineering
|
Handschin, Christoph |
|
2015 |
163-164 |
C |
p. 168-175 8 p. |
artikel |
846 |
External stimulus responsive inorganic nanomaterials for cancer theranostics
|
M., Sheikh Mohamed |
|
2019 |
163-164 |
C |
p. 18-40 |
artikel |
847 |
Extracellular matrix component signaling in cancer
|
Multhaupt, Hinke A.B. |
|
2016 |
163-164 |
C |
p. 28-40 13 p. |
artikel |
848 |
Extracellular matrix-inspired growth factor delivery systems for bone regeneration
|
Martino, Mikaël M. |
|
2015 |
163-164 |
C |
p. 41-52 12 p. |
artikel |
849 |
Extracellular matrix structure
|
Theocharis, Achilleas D. |
|
2016 |
163-164 |
C |
p. 4-27 24 p. |
artikel |
850 |
Extracellular signaling molecules to promote fracture healing and bone regeneration
|
Hankenson, K.D. |
|
2015 |
163-164 |
C |
p. 3-12 10 p. |
artikel |
851 |
Extracellular vesicle-associated lipids in central nervous system disorders
|
Vanherle, Sam |
|
|
163-164 |
C |
p. 322-331 |
artikel |
852 |
Extracellular vesicle-associated small heat shock proteins as therapeutic agents in neurodegenerative diseases and beyond
|
Van den Broek, Bram |
|
|
163-164 |
C |
p. |
artikel |
853 |
Extracellular vesicles are key players in mesenchymal stem cells’ dual potential to regenerate and modulate the immune system
|
van Griensven, Martijn |
|
|
163-164 |
C |
p. |
artikel |
854 |
Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies
|
Escudé Martinez de Castilla, Pol |
|
|
163-164 |
C |
p. |
artikel |
855 |
Extracellular vesicles as antigen carriers for novel vaccination avenues
|
Mehanny, Mina |
|
|
163-164 |
C |
p. 164-180 |
artikel |
856 |
Extracellular vesicles as delivery systems at nano-/micro-scale
|
Fu, Peiwen |
|
|
163-164 |
C |
p. |
artikel |
857 |
Extracellular vesicles as drug delivery systems: Why and how?
|
Elsharkasy, Omnia M. |
|
|
163-164 |
C |
p. 332-343 |
artikel |
858 |
Extracellular vesicles as modulators of wound healing
|
Cabral, Joana |
|
|
163-164 |
C |
p. 394-406 |
artikel |
859 |
Extracellular vesicles as novel assay tools to study cellular interactions of anti-infective compounds – A perspective
|
Richter, Robert |
|
|
163-164 |
C |
p. 492-503 |
artikel |
860 |
Extracellular vesicles for improved tumor accumulation and penetration
|
Bie, Nana |
|
|
163-164 |
C |
p. |
artikel |
861 |
Extracellular vesicles for personalized medicine: The input of physically triggered production, loading and theranostic properties
|
Piffoux, Max |
|
2019 |
163-164 |
C |
p. 247-258 |
artikel |
862 |
Extracellular vesicles for the treatment of central nervous system diseases
|
Gratpain, Viridiane |
|
|
163-164 |
C |
p. 535-552 |
artikel |
863 |
Extracellular vesicles for tissue repair and regeneration: Evidence, challenges and opportunities
|
Nagelkerke, Anika |
|
|
163-164 |
C |
p. |
artikel |
864 |
Extracellular vesicles from mesenchymal stromal cells: Therapeutic perspectives for targeting senescence in osteoarthritis
|
Boulestreau, Jérémy |
|
|
163-164 |
C |
p. |
artikel |
865 |
Extracellular vesicles over adeno-associated viruses: Advantages and limitations as drug delivery platforms in precision medicine
|
Yom-Tov, Nataly |
|
|
163-164 |
C |
p. |
artikel |
866 |
Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids
|
Bader, Johannes |
|
|
163-164 |
C |
p. |
artikel |
867 |
Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines
|
Nakamura, Takashi |
|
|
163-164 |
C |
p. |
artikel |
868 |
Fatty acid metabolism in the progression and resolution of CNS disorders
|
Bogie, Jeroen F.J. |
|
|
163-164 |
C |
p. 198-213 |
artikel |
869 |
Ferritin nanocage: A promising and designable multi-module platform for constructing dynamic nanoassembly-based drug nanocarrier
|
Zhang, Baoli |
|
|
163-164 |
C |
p. |
artikel |
870 |
Fibrillin microfibrils and proteases, key integrators of fibrotic pathways
|
Zigrino, Paola |
|
2019 |
163-164 |
C |
p. 3-16 |
artikel |
871 |
Fibrin-based delivery strategies for acute and chronic wound healing
|
Heher, P. |
|
|
163-164 |
C |
p. 134-147 |
artikel |
872 |
Fibroblasts and extracellular matrix: Targeting and therapeutic tools in fibrosis and cancer
|
Prakash, Jai |
|
2017 |
163-164 |
C |
p. 1-2 |
artikel |
873 |
Fibronectin in development and wound healing
|
Patten, Jennifer |
|
|
163-164 |
C |
p. 353-368 |
artikel |
874 |
Fibronectin-targeted drug delivery in cancer
|
Kumra, Heena |
|
2016 |
163-164 |
C |
p. 101-110 10 p. |
artikel |
875 |
Fibrosis imaging: Current concepts and future directions
|
Baues, Maike |
|
2017 |
163-164 |
C |
p. 9-26 |
artikel |
876 |
Fibrosis in tissue engineering and regenerative medicine: treat or trigger?
|
Fernández-Colino, Alicia |
|
2019 |
163-164 |
C |
p. 17-36 |
artikel |
877 |
Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities
|
Tuleta, Izabela |
|
|
163-164 |
C |
p. |
artikel |
878 |
Fibrous scaffolds for building hearts and heart parts
|
Capulli, A.K. |
|
2016 |
163-164 |
C |
p. 83-102 20 p. |
artikel |
879 |
Fit and forget: The future of dental implant therapy via nanotechnology
|
Gulati, Karan |
|
|
163-164 |
C |
p. |
artikel |
880 |
Fluorescence anisotropy imaging in drug discovery
|
Vinegoni, Claudio |
|
|
163-164 |
C |
p. 262-288 |
artikel |
881 |
Fluorescence microscopic platforms imaging mitochondrial abnormalities in neurodegenerative diseases
|
Wang, Yicheng |
|
|
163-164 |
C |
p. |
artikel |
882 |
Fluorescent imaging of cancerous tissues for targeted surgery
|
Bu, Lihong |
|
2014 |
163-164 |
C |
p. 21-38 18 p. |
artikel |
883 |
Formulation and stabilization of recombinant protein based virus-like particle vaccines
|
Jain, Nishant K. |
|
2015 |
163-164 |
C |
p. 42-55 14 p. |
artikel |
884 |
Formulation strategies for bacteriophages to target intracellular bacterial pathogens
|
Yan, Wei |
|
|
163-164 |
C |
p. |
artikel |
885 |
Formulation strategies to improve the efficacy of intestinal permeation enhancers,
|
Maher, Sam |
|
|
163-164 |
C |
p. |
artikel |
886 |
From bench to FDA to bedside: US regulatory trends for new stem cell therapies
|
Knoepfler, Paul S. |
|
2015 |
163-164 |
C |
p. 192-196 5 p. |
artikel |
887 |
From cell-SELEX to tissue-SELEX for targeted drug delivery and aptamer nanomedicine
|
Wong, Ka-Ying |
|
|
163-164 |
C |
p. |
artikel |
888 |
From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer
|
Gonzales-Aloy, Estrella |
|
|
163-164 |
C |
p. |
artikel |
889 |
From cells to subcellular organelles: Next-generation cancer therapy based on peptide self-assembly
|
Liu, Huayang |
|
|
163-164 |
C |
p. |
artikel |
890 |
From concept to early clinical trials: 30 years of microbubble-based ultrasound-mediated drug delivery research
|
Bouakaz, Ayache |
|
|
163-164 |
C |
p. |
artikel |
891 |
From in vitro to in vivo: A comprehensive guide to IVIVC development for long-acting therapeutics
|
Pastorin, Giorgia |
|
|
163-164 |
C |
p. |
artikel |
892 |
From the gut to the blood–brain barrier: Novel approaches for the treatment and targeted delivery of therapeutics in Alzheimer’s disease
|
Nicolazzo, Joseph A. |
|
|
163-164 |
C |
p. |
artikel |
893 |
Frontiers in the treatment of glioblastoma: Past, present and emerging
|
Janjua, Taskeen Iqbal |
|
|
163-164 |
C |
p. 108-138 |
artikel |
894 |
Functional antibody delivery: Advances in cellular manipulation
|
Koch, Kayla C. |
|
|
163-164 |
C |
p. |
artikel |
895 |
Functional peptides for siRNA delivery
|
Tai, Wanyi |
|
2017 |
163-164 |
C |
p. 157-168 12 p. |
artikel |
896 |
Functional regeneration at the blood-biomaterial interface
|
Ibrahim, Dina M. |
|
|
163-164 |
C |
p. |
artikel |
897 |
Functional therapies for cutaneous wound repair in epidermolysis bullosa
|
Peking, Patricia |
|
|
163-164 |
C |
p. 330-343 |
artikel |
898 |
Fundamentals of fractional laser-assisted drug delivery: An in-depth guide to experimental methodology and data interpretation
|
Wenande, Emily |
|
|
163-164 |
C |
p. 169-184 |
artikel |
899 |
Fungal infections: Immune defense, immunotherapies and vaccines
|
Loh, Jia Tong |
|
|
163-164 |
C |
p. |
artikel |
900 |
Fusobacterium nucleatum carcinogenesis and drug delivery interventions
|
Chen, Zhenzhen |
|
|
163-164 |
C |
p. |
artikel |
901 |
“Future Directions” – Novel breakthrough developments in the fields of drug development & delivery, and regenerative medicine
|
Schenke-Layland, Katja |
|
|
163-164 |
C |
p. |
artikel |
902 |
Gasotransmitter delivery via self-assembling peptides: Treating diseases with natural signaling gases
|
Qian, Yun |
|
2017 |
163-164 |
C |
p. 137-156 20 p. |
artikel |
903 |
Gelatin-integrated carbon nanomaterials in nanomedicine: From biosensing and bioprinting to tissue engineering and other biomedical applications
|
Saeidirad, Mahdi |
|
|
163-164 |
C |
p. |
artikel |
904 |
Gene and cell therapy for children — New medicines, new challenges?
|
Buckland, Karen F. |
|
2014 |
163-164 |
C |
p. 162-169 8 p. |
artikel |
905 |
Gene- and RNAi-activated scaffolds for bone tissue engineering: Current progress and future directions
|
Laird, Noah Z. |
|
|
163-164 |
C |
p. 613-627 |
artikel |
906 |
Gene delivery nanoparticles to modulate angiogenesis
|
Kim, Jayoung |
|
2017 |
163-164 |
C |
p. 20-43 |
artikel |
907 |
Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses
|
Fachel, Flávia Nathiely Silveira |
|
|
163-164 |
C |
p. |
artikel |
908 |
Gene editing therapeutics based on mRNA delivery
|
Popovitz, Juliana |
|
|
163-164 |
C |
p. |
artikel |
909 |
Gene regulation in adult neural stem cells. Current challenges and possible applications
|
Encinas, Juan Manuel |
|
2017 |
163-164 |
C |
p. 118-132 |
artikel |
910 |
Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: Progress towards non-viral systems
|
Hakim, Antoine |
|
|
163-164 |
C |
p. |
artikel |
911 |
Genome stability of programmed stem cell products
|
Martin, Ulrich |
|
2017 |
163-164 |
C |
p. 108-117 |
artikel |
912 |
Get out or die trying: Peptide- and protein-based endosomal escape of RNA therapeutics
|
Klipp, Alexander |
|
|
163-164 |
C |
p. |
artikel |
913 |
Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS
|
Nair, Madhavan |
|
|
163-164 |
C |
p. 202-217 |
artikel |
914 |
GLP: A requirement in cell therapies - perspectives for the cardiovascular field
|
Müller-Ruch, Ulrike |
|
|
163-164 |
C |
p. 96-104 |
artikel |
915 |
Glycomacromolecules: Addressing challenges in drug delivery and therapeutic development
|
Stuart-Walker, Will |
|
|
163-164 |
C |
p. 77-93 |
artikel |
916 |
GO-based antibacterial composites: Application and design strategies
|
Hu, Chen |
|
|
163-164 |
C |
p. |
artikel |
917 |
Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements
|
Her, Sohyoung |
|
2017 |
163-164 |
C |
p. 84-101 18 p. |
artikel |
918 |
Growth factor and small molecule influence on urological tissue regeneration utilizing cell seeded scaffolds
|
Sharma, Arun K. |
|
2015 |
163-164 |
C |
p. 86-92 7 p. |
artikel |
919 |
Guest Editorial Title: Nanomedicine: past, present, and future
|
Moon, James J. |
|
2018 |
163-164 |
C |
p. 1-2 |
artikel |
920 |
Guiding immunotherapy combinations: Who gets what?
|
Ferreira, Michelle N. |
|
|
163-164 |
C |
p. |
artikel |
921 |
Gut-brain-immune interactions: exploring probiotics as a drug delivery platform for neurological disease
|
Gudi, Chinmayi R. |
|
|
163-164 |
C |
p. |
artikel |
922 |
β-hairpin peptide hydrogels for package delivery
|
Worthington, Peter |
|
2017 |
163-164 |
C |
p. 127-136 10 p. |
artikel |
923 |
Harnessing albumin as a carrier for cancer therapies
|
Hoogenboezem, Ella N. |
|
2018 |
163-164 |
C |
p. 73-89 |
artikel |
924 |
Harnessing anti-inflammatory pathways and macrophage nano delivery to treat inflammatory and fibrotic disorders
|
Zaid, Ahmad |
|
|
163-164 |
C |
p. |
artikel |
925 |
Harnessing artificial intelligence for the next generation of 3D printed medicines
|
Elbadawi, Moe |
|
|
163-164 |
C |
p. |
artikel |
926 |
Harnessing carbon nanomaterials for reactive oxygen species regulation: Insights into generation, scavenging, and sensing
|
Liu, Zhanpeng (Jim) |
|
|
163-164 |
C |
p. |
artikel |
927 |
Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues
|
Naseri Kouzehgarani, Ghazal |
|
|
163-164 |
C |
p. 20-59 |
artikel |
928 |
Harnessing epigenetic inhibitors: A promising approach for overcoming challenges in pancreatic ductal adenocarcinoma treatment
|
Maietta, Immacolata |
|
|
163-164 |
C |
p. |
artikel |
929 |
Harnessing EV communication to restore antitumor immunity
|
Massaro, Crescenzo |
|
|
163-164 |
C |
p. |
artikel |
930 |
Harnessing immune response using reactive oxygen Species-Generating/Eliminating inorganic biomaterials for disease treatment
|
Zhao, Caiyan |
|
|
163-164 |
C |
p. |
artikel |
931 |
Harnessing macrophage plasticity for tissue regeneration
|
Smith, Tim D. |
|
2017 |
163-164 |
C |
p. 193-205 |
artikel |
932 |
Harnessing molecular recognition for localized drug delivery
|
Liu, Renjie |
|
|
163-164 |
C |
p. 238-260 |
artikel |
933 |
Heparin coatings for improving blood compatibility of medical devices
|
Biran, Roy |
|
2017 |
163-164 |
C |
p. 12-23 12 p. |
artikel |
934 |
Hepatic stellate cells as key target in liver fibrosis
|
Higashi, Takaaki |
|
2017 |
163-164 |
C |
p. 27-42 |
artikel |
935 |
Hepatocellular carcinoma and microRNA: New perspectives on therapeutics and diagnostics
|
Yang, Ningning |
|
2015 |
163-164 |
C |
p. 62-74 13 p. |
artikel |
936 |
Highly branched poly(β-amino ester)s for gene delivery in hereditary skin diseases
|
Zeng, Ming |
|
|
163-164 |
C |
p. |
artikel |
937 |
High-throughput proteomics and AI for cancer biomarker discovery
|
Xiao, Qi |
|
|
163-164 |
C |
p. |
artikel |
938 |
Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models
|
Too, Nathaniel Sheng Hua |
|
|
163-164 |
C |
p. |
artikel |
939 |
How can machine learning and multiscale modeling benefit ocular drug development?
|
Wang, Nannan |
|
|
163-164 |
C |
p. |
artikel |
940 |
How does the pathophysiological context influence delivery of bone growth factors?
|
Yu, Xiaohua |
|
2015 |
163-164 |
C |
p. 68-84 17 p. |
artikel |
941 |
How multi-organ microdevices can help foster drug development
|
Esch, Mandy B. |
|
2014 |
163-164 |
C |
p. 158-169 12 p. |
artikel |
942 |
hPSC-based treatment of retinal diseases – Current progress and challenges
|
Ozaki, Atsuta |
|
|
163-164 |
C |
p. |
artikel |
943 |
Human engineered heart tissue as a model system for drug testing
|
Eder, Alexandra |
|
2016 |
163-164 |
C |
p. 214-224 11 p. |
artikel |
944 |
Human immunity in vitro — Solving immunogenicity and more
|
Giese, Christoph |
|
2014 |
163-164 |
C |
p. 103-122 20 p. |
artikel |
945 |
Human ocular mucins: The endowed guardians of sight
|
Argüeso, Pablo |
|
|
163-164 |
C |
p. |
artikel |
946 |
Human pathological basis of blood vessels and stromal tissue for nanotechnology
|
Nishihara, Hiroshi |
|
2014 |
163-164 |
C |
p. 19-27 9 p. |
artikel |
947 |
Human pluripotent stem cell-based cardiac repair: Lessons learned and challenges ahead
|
Montague, E.Coulter |
|
|
163-164 |
C |
p. |
artikel |
948 |
Human pluripotent stem cells: Prospects and challenges as a source of cardiomyocytes for in vitro modeling and cell-based cardiac repair
|
Hartman, Matthew E. |
|
2016 |
163-164 |
C |
p. 3-17 15 p. |
artikel |
949 |
Human skin equivalents: Impaired barrier function in relation to the lipid and protein properties of the stratum corneum
|
Bouwstra, Joke A. |
|
|
163-164 |
C |
p. |
artikel |
950 |
HuR as a molecular target for cancer therapeutics and immune-related disorders
|
Majumder, Mrinmoyee |
|
|
163-164 |
C |
p. |
artikel |
951 |
Hurdles in translating science from lab to market in delivery systems for Cosmetics: An industrial perspective
|
Siqueira Andrade, Sheila |
|
|
163-164 |
C |
p. |
artikel |
952 |
HuR-targeted agents: An insight into medicinal chemistry, biophysical, computational studies and pharmacological effects on cancer models
|
Assoni, Giulia |
|
|
163-164 |
C |
p. |
artikel |
953 |
Hyaluronan as a therapeutic target in human diseases
|
Liang, Jiurong |
|
2016 |
163-164 |
C |
p. 186-203 18 p. |
artikel |
954 |
Hyaluronan as tunable drug delivery system
|
Passi, Alberto |
|
2019 |
163-164 |
C |
p. 83-96 |
artikel |
955 |
Hyaluronic acid for anticancer drug and nucleic acid delivery
|
Dosio, Franco |
|
2016 |
163-164 |
C |
p. 204-236 33 p. |
artikel |
956 |
Hybrid drug nanocrystals
|
Lu, Yi |
|
|
163-164 |
C |
p. 115-133 |
artikel |
957 |
Hydrogel-based approaches to target hypersensitivity mechanisms underlying autoimmune disease
|
Kim, Kenneth M. |
|
|
163-164 |
C |
p. |
artikel |
958 |
Hydrogels for therapeutic cardiovascular angiogenesis
|
Rufaihah, Abdul Jalil |
|
2016 |
163-164 |
C |
p. 31-39 9 p. |
artikel |
959 |
Hydrogels to model 3D in vitro microenvironment of tumor vascularization
|
Song, Hyun-Ho Greco |
|
2014 |
163-164 |
C |
p. 19-29 11 p. |
artikel |
960 |
Hydrogel vehicles for sequential delivery of protein drugs to promote vascular regeneration
|
Wei, Zhao |
|
|
163-164 |
C |
p. 95-106 |
artikel |
961 |
Hyperthermia and smart drug delivery systems for solid tumor therapy
|
Seynhaeve, A.L.B. |
|
|
163-164 |
C |
p. 125-144 |
artikel |
962 |
Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy
|
Dunne, Michael |
|
|
163-164 |
C |
p. 98-124 |
artikel |
963 |
Illuminating RNA trafficking and functional delivery by extracellular vesicles
|
de Voogt, Willemijn S. |
|
|
163-164 |
C |
p. 250-264 |
artikel |
964 |
Image-guided drug delivery: Biomedical and imaging advances
|
Sofias, Alexandros Marios |
|
|
163-164 |
C |
p. |
artikel |
965 |
Image-guided drug delivery in nanosystem-based cancer therapies
|
Priester, Marjolein I. |
|
|
163-164 |
C |
p. |
artikel |
966 |
Image-guided drug delivery: Nanoparticle and probe advances
|
Guo, Bing |
|
|
163-164 |
C |
p. |
artikel |
967 |
Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles
|
Phillips, William T. |
|
2014 |
163-164 |
C |
p. 39-59 21 p. |
artikel |
968 |
Image-guided intratumoral immunotherapy: Developing a clinically practical technology
|
Som, Avik |
|
|
163-164 |
C |
p. |
artikel |
969 |
Imaging and quantifying drug delivery in skin – Part 1: Autoradiography and mass spectrometry imaging
|
Grégoire, Sébastien |
|
|
163-164 |
C |
p. 137-146 |
artikel |
970 |
Imaging and quantifying drug delivery in skin – Part 2: Fluorescence andvibrational spectroscopic imaging methods
|
Pena, Ana-Maria |
|
|
163-164 |
C |
p. 147-168 |
artikel |
971 |
Imaging and therapeutic applications of persistent luminescence nanomaterials
|
Liu, Jianhua |
|
2019 |
163-164 |
C |
p. 193-210 |
artikel |
972 |
Imaging and therapeutic targeting of the tumor immune microenvironment with biologics
|
Arnouk, Sana |
|
|
163-164 |
C |
p. |
artikel |
973 |
Imaging and therapy of diabetes: State of the art
|
Cai, Weibo |
|
2019 |
163-164 |
C |
p. 1-2 |
artikel |
974 |
Imaging drug delivery to the lungs: Methods and applications in oncology
|
Man, Francis |
|
|
163-164 |
C |
p. |
artikel |
975 |
Imaging-guided delivery of RNAi for anticancer treatment
|
Wang, Junqing |
|
2016 |
163-164 |
C |
p. 44-60 17 p. |
artikel |
976 |
Imaging-guided/improved diseases management for immune-strategies and beyond
|
Zhang, Tian |
|
|
163-164 |
C |
p. |
artikel |
977 |
Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
|
Sun, Juan |
|
|
163-164 |
C |
p. |
artikel |
978 |
Imaging regional lung function: A critical tool for developing inhaled antimicrobial therapies
|
Dubsky, Stephen |
|
2015 |
163-164 |
C |
p. 100-109 10 p. |
artikel |
979 |
Imaging technology of the lymphatic system
|
Polomska, Anna K. |
|
|
163-164 |
C |
p. 294-311 |
artikel |
980 |
Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior
|
Miller, Miles A. |
|
2017 |
163-164 |
C |
p. 61-86 26 p. |
artikel |
981 |
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
|
Maulana, Tengku Ibrahim |
|
|
163-164 |
C |
p. 281-305 |
artikel |
982 |
Immunoengineering strategies to enhance vascularization and tissue regeneration
|
Zarubova, Jana |
|
|
163-164 |
C |
p. |
artikel |
983 |
Immuno-engineering: The Next Frontier in Therapeutics Delivery
|
Singh, Ankur |
|
2017 |
163-164 |
C |
p. 1-2 |
artikel |
984 |
Immunological perspectives on spatial and temporal vaccine delivery
|
Zhu, Mingzhao |
|
|
163-164 |
C |
p. |
artikel |
985 |
Immunology of carbohydrate-based vaccines
|
Khatun, Farjana |
|
|
163-164 |
C |
p. 117-126 |
artikel |
986 |
Immunophenotyping: Analytical approaches and role in preclinical development of nanomedicines
|
Newton, Hannah S. |
|
|
163-164 |
C |
p. |
artikel |
987 |
Immunoprotection of cellular transplants for autoimmune type 1 diabetes through local drug delivery
|
Lansberry, T.R. |
|
|
163-164 |
C |
p. |
artikel |
988 |
Immuno-regenerative biomaterials for in situ cardiovascular tissue engineering – Do patient characteristics warrant precision engineering?
|
de Kort, B.J. |
|
|
163-164 |
C |
p. |
artikel |
989 |
Immunotherapies for locally aggressive cancers
|
Adams, Sarah C. |
|
|
163-164 |
C |
p. |
artikel |
990 |
Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment
|
Zhang, Jie |
|
|
163-164 |
C |
p. |
artikel |
991 |
Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics
|
Pan, Yijun |
|
2018 |
163-164 |
C |
p. 62-74 |
artikel |
992 |
Impact of particle elasticity on particle-based drug delivery systems
|
Anselmo, Aaron C. |
|
2017 |
163-164 |
C |
p. 51-67 17 p. |
artikel |
993 |
Impact of the host microbiota on fungal infections: New possibilities for intervention?
|
Chow, Eve W.L. |
|
|
163-164 |
C |
p. |
artikel |
994 |
Implantable Micro-Light-Emitting Diode (µLED)-based optogenetic interfaces toward human applications
|
Hee Lee, Jae |
|
|
163-164 |
C |
p. |
artikel |
995 |
Implantable systems for neurological chronotherapy
|
Lee, Seung Ho |
|
|
163-164 |
C |
p. |
artikel |
996 |
Implications and pitfalls for cancer diagnostics exploiting extracellular vesicles
|
Špilak, Ana |
|
|
163-164 |
C |
p. |
artikel |
997 |
Implications of melanin binding in ocular drug delivery
|
Rimpelä, Anna-Kaisa |
|
2018 |
163-164 |
C |
p. 23-43 |
artikel |
998 |
Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery
|
Pechenov, Sergei |
|
2017 |
163-164 |
C |
p. 106-122 17 p. |
artikel |
999 |
Improving long-term subcutaneous drug delivery by regulating material-bioenvironment interaction
|
Chen, Wei |
|
|
163-164 |
C |
p. 20-34 |
artikel |
1000 |
Improving the efficacy of inhaled drugs for severe lung diseases: Emerging pulmonary delivery strategies
|
Ungaro, Francesca |
|
2014 |
163-164 |
C |
p. 1-2 2 p. |
artikel |